Haemonetics (HAE) 10-K 1 Jun 16 2016 FY Annual report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
	Apr. 02, 2016	May. 20, 2016	Sep. 26, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	313,143
Current Fiscal Year End Date	--04-02
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Apr. 2, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,042,696
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,738,830,869

CONSOLIDATED STATEMENTS OF (LOS

CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Income Statement [Abstract]
Net revenues	$ 908,832	$ 910,373	$ 938,509
Cost of goods sold	502,918	475,955	470,144
Gross profit	405,914	434,418	468,365
Operating expenses:
Research and development	44,965	54,187	54,200
Selling, general and administrative	317,223	337,168	365,977
Impairment of assets	92,395	5,441	1,711
Contingent consideration (income) expense	(4,727)	(2,918)	45
Total operating expenses	449,856	393,878	421,933
Operating (loss) income	(43,942)	40,540	46,432
Other expense, net	(9,474)	(9,375)	(10,031)
(Loss) income before provision for income taxes	(53,416)	31,165	36,401
Provision for income taxes	2,163	14,268	1,253
Net (loss) income	$ (55,579)	$ 16,897	$ 35,148
Net (loss) income per share - basic (in dollars per share)	$ (1.09)	$ 0.33	$ 0.68
Net (loss) income per share - diluted (in dollars per share)	$ (1.09)	$ 0.32	$ 0.67
Weighted average shares outstanding
Basic (in shares)	50,910	51,533	51,611
Diluted (in shares)	50,910	52,089	52,377

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (55,579)	$ 16,897	$ 35,148
Other comprehensive loss:
Impact of defined benefit plans, net of tax	1,431	(4,331)	481
Foreign currency translation adjustment	(1,987)	(23,710)	(935)
Unrealized (loss) gain on cash flow hedges, net of tax	(3,938)	11,371	5,001
Reclassifications into earnings of cash flow hedge gains, net of tax	(8,822)	(6,464)	(8,570)
Other comprehensive loss	(13,316)	(23,134)	(4,023)
Comprehensive (loss) income	$ (68,895)	$ (6,237)	$ 31,125

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 02, 2016	Mar. 28, 2015
Current assets:
Cash and cash equivalents	$ 115,123	$ 160,662
Accounts receivable, less allowance of $2,253 at April 2, 2016 and $1,749 at March 28, 2015	157,093	145,827
Inventories, net	187,028	211,077
Prepaid expenses and other current assets	28,842	40,103
Total current assets	488,086	557,669
Property, plant and equipment, net	337,634	321,948
Intangible assets, less accumulated amortization of $190,816 at April 2, 2016 and $133,175 at March 28, 2015	204,458	244,588
Goodwill	267,840	334,310
Deferred tax asset, long term	7,055	15,631
Other long-term assets	14,055	11,271
Total assets	1,319,128	1,485,417
Current liabilities:
Notes payable and current maturities of long-term debt	43,471	21,522
Accounts payable	39,674	48,425
Accrued payroll and related costs	35,798	51,115
Other current liabilities	66,608	67,622
Total current liabilities	185,551	188,684
Long-term debt, net of current maturities	364,529	406,369
Long-term deferred tax liability	21,377	32,505
Other long-term liabilities	26,106	31,737
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,932,348 shares at April 2, 2016 and 51,670,969 shares at March 28, 2015	509	517
Additional paid-in capital	439,912	426,964
Retained earnings	316,184	420,365
Accumulated other comprehensive loss	(35,040)	(21,724)
Total stockholders’ equity	721,565	826,122
Total liabilities and stockholders’ equity	$ 1,319,128	$ 1,485,417

CONSOLIDATED BALANCE SHEETS (PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Apr. 02, 2016	Mar. 28, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,253	$ 1,749
Intangible assets, accumulated amortization	$ 190,816	$ 133,175
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	50,932,348	51,670,969
Common stock, outstanding (in shares)	50,932,348	51,670,969

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
Balance, value at Mar. 30, 2013	$ 769,182	$ 510	$ 365,040	$ 398,199	$ 5,433
Balance, shares (in shares) at Mar. 30, 2013		51,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	5,229	$ 2	5,227
Employee stock purchase plan (in shares)		161
Exercise of stock options and related tax benefit	19,270	$ 7	19,263
Exercise of stock options and related tax benefit (in shares)		740
Stock-based compensation adjustment related to acquisition	0
Shares repurchased	0
Issuance of restricted stock, net of cancellations	1	$ 1
Share-based Compensation	13,082
Issuance of restricted stock, net of cancellations (in shares)		108
Stock compensation expense	13,081		13,081
Net (loss) income	35,148
Other comprehensive loss	(4,023)
Balance, value at Mar. 29, 2014	837,888	$ 520	402,611	433,347	1,410
Balance, shares (in shares) at Mar. 29, 2014		52,041
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,763	$ 2	4,761
Employee stock purchase plan (in shares)		183
Exercise of stock options and related tax benefit	14,645	$ 5	14,640
Exercise of stock options and related tax benefit (in shares)		500
Shares repurchased	(39,033)	$ (11)	(9,143)	(29,879)
Shares repurchased (in shares)		(1,174)
Issuance of restricted stock, net of cancellations	1	$ 1
Share-based Compensation	14,095
Issuance of restricted stock, net of cancellations (in shares)		121
Stock compensation expense	14,095		14,095
Net (loss) income	16,897
Other comprehensive loss	(23,134)
Balance, value at Mar. 28, 2015	826,122	$ 517	426,964	420,365	(21,724)
Balance, shares (in shares) at Mar. 28, 2015		51,671
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,341	$ 1	4,340
Employee stock purchase plan (in shares)		145
Exercise of stock options and related tax benefit	14,032	$ 6	14,026
Exercise of stock options and related tax benefit (in shares)		492
Shares repurchased	(60,984)	$ (15)	(12,367)	(48,602)
Shares repurchased (in shares)		(1,488)
Issuance of restricted stock, net of cancellations	0
Share-based Compensation	6,949
Issuance of restricted stock, net of cancellations (in shares)		112
Stock compensation expense	6,949
Net (loss) income	(55,579)
Other comprehensive loss	(13,316)
Balance, value at Apr. 02, 2016	$ 721,565	$ 509	$ 439,912	$ 316,184	$ (35,040)
Balance, shares (in shares) at Apr. 02, 2016		50,932

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Cash Flows from Operating Activities:
Net (loss) income	$ (55,579)	$ 16,897	$ 35,148
Non-cash items:
Depreciation and amortization	89,911	86,053	81,740
Impairment of assets	101,243	5,877	2,587
Stock compensation expense	6,949	14,095	13,082
Deferred tax (benefit) expense	(1,038)	4,230	1,736
Unrealized (gain)/loss from hedging activities	(2,645)	1,558	(128)
Changes in fair value of contingent consideration	(4,727)	(2,918)	45
Provision for losses on accounts receivable and inventory	13,053	4,972	3,020
Other non-cash operating activities	899	1,055	5,367
Change in operating assets and liabilities:
Change in accounts receivable, net	(10,328)	8,446	6,063
Change in inventories	11,896	(21,515)	(15,613)
Change in prepaid income taxes	(651)	10,662	1,175
Change in other assets and other liabilities	3,121	(8,013)	3,176
Tax benefit of exercise of stock options	0	3,786	1,649
Change in accounts payable and accrued expenses	(30,239)	1,993	477
Net cash provided by operating activities	121,865	127,178	139,524
Cash Flows from Investing Activities:
Capital expenditures	(102,405)	(122,220)	(73,648)
Proceeds from sale of property, plant and equipment	637	452	488
Acquisition of Hemerus	0	0	(23,124)
Other acquisitions and investments	(3,000)	0	(9,546)
Net cash used in investing activities	(104,768)	(121,768)	(105,830)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(943)	(1,048)	(964)
Net increase (decrease) in short-term loans	2,272	843	(5,521)
Repayment of term loan borrowings	(21,342)	(8,531)	(37,063)
Proceeds from employee stock purchase plan	4,341	4,763	5,229
Proceeds from exercise of stock options	14,032	9,290	15,225
Share repurchases	(60,984)	(39,033)	0
Other financing activities	0	556	2,395
Net cash used in financing activities	(62,624)	(33,160)	(20,699)
Effect of exchange rates on cash and cash equivalents	(12)	(4,057)	354
Net Change in Cash and Cash Equivalents	(45,539)	(31,807)	13,349
Cash and Cash Equivalents at Beginning of Year	160,662	192,469	179,120
Cash and Cash Equivalents at End of Year	115,123	160,662	192,469
Supplemental Disclosures of Cash Flow Information:
Interest paid	8,511	8,497	8,942
Income taxes paid	7,829	11,211	7,261
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 9,663	$ 7,458	$ 10,584

DESCRIPTION OF THE BUSINESS AND

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Apr. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global healthcare company dedicated to providing innovative products to customers involved in the processing, handling and analysis of blood. We offer a comprehensive portfolio of integrated devices and information management tools with the goal of helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. Blood and its components (plasma, platelets, and red cells) have many vital - and frequently life-saving - clinical applications. Plasma is used for patients with major blood loss and is manufactured into pharmaceuticals to treat a variety of illnesses and hereditary disorders such as hemophilia. Red cells treat trauma patients or patients undergoing surgery with high blood loss, such as open heart surgery or organ transplant. Platelets treat cancer patients undergoing chemotherapy. Blood is essential to a modern healthcare system. Haemonetics develops and markets a wide range of devices and solutions to serve our customers. We provide plasma collection systems and software which enable plasma fractionators to make life saving pharmaceuticals. We provide analytical devices for measuring hemostasis which enable healthcare providers to better manage their patients’ bleeding risk. Haemonetics makes blood processing systems and software which make blood donation more efficient and track life giving blood components. Finally, Haemonetics supplies systems and software which facilitate blood transfusions and cell processing. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The accompanying consolidated financial statements present separately our financial position, results of operations, cash flows, and changes in shareholders’ equity. All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Refer to Note 15, Restructuring, for information pertaining to our new restructuring initiative, which was approved after the balance sheet date but prior to the issuance of the financial statements. There were no other material subsequent events identified.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Apr. 02, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fiscal Year Our fiscal year ends on the Saturday closest to the last day of March. Fiscal year 2016 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks. Fiscal year 2015 and 2014 included 52 weeks with each quarter having 13 weeks. Principles of Consolidation The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions. We consider estimates to be critical if we are required to make assumptions about material matters that are uncertain at the time of estimation or if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: revenue recognition, allowance for doubtful accounts, inventory provisions, intangible asset and goodwill valuation, legal and other judgmental accruals, and income taxes. Reclassifications Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation. Contingencies We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, employee related litigation, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a loss is probable and a range of loss is established but a best estimate cannot be made, we record the minimum loss contingency amount, which could be zero. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. As information becomes known, an additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount. Revenue Recognition Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition , and ASC Topic 985-605, Software . These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software , we establish fair value of undelivered elements based upon vendor specific objective evidence. We offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum potential rebate or discount that could be earned. In circumstances where we provide upfront rebate payments to customers, we capitalize the rebate payments and amortize the resulting asset as a reduction of revenue using a systematic method over the life of the contract. Product Revenues Product sales consist of the sale of our disposable blood component collection and processing sets and the related equipment. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product. We also place equipment at customer sites. While we retain ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. We recover the cost of providing the equipment from the sale of disposables. Software Revenues Our software solutions business provides support to our plasma, blood collection and hospital customers. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. For hospitals, we provide solutions to help improve patient safety, reduce cost and ensure compliance. Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees. We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period. Non-Income Taxes We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority. We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses. In December 2015, this tax was suspended for two years, beginning on January 1, 2016. This tax may be imposed again beginning on January 1, 2018, unless the suspension is extended or the medical device excise tax is permanently repealed. Translation of Foreign Currencies All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of (loss) income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss on the consolidated balance sheet. Cash and Cash Equivalents Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of April 2, 2016 , our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds. Allowance for Doubtful Accounts We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience. Inventories Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. We have based our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. Significant changes in the timing or level of demand for our products results in recording additional provisions for excess, expired and obsolete inventory. Additionally, uncertain timing of next-generation product approvals, variability in product launch strategies, non-cancelable purchase commitments, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Property, Plant and Equipment Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows: Asset Classification Estimated Useful Lives Building 30 Years Building improvements 5-20 Years Plant equipment and machinery 3-15 Years Office equipment and information technology 2-10 Years Haemonetics equipment 3-7 Years We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following: • Purchase and consumption of a certain level of disposable products • Payment of monthly rental fees • An asset utilization performance metric, such as performing a minimum level of procedures per month per device Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for disposables used with these devices, from which we generate revenues. We also consider product life cycle in our evaluation of useful life and recoverability. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income. Goodwill and Intangible Assets Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("Topic 350"), or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. In performing our goodwill impairment assessment, we utilize the two-step approach prescribed under Topic 350. The first step requires a comparison of the carrying value of the reporting units, as defined, to the fair value of these units. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We determine our reporting units by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. We aggregate components within an operating segment that have similar economic characteristics. Our reporting units for purposes of assessing goodwill impairment are the same as our operating segments, which are organized primarily based on geography and include: (a) North America Plasma, (b) Americas Blood Center and Hospital, (c) Europe, Middle East, and Africa (collectively "EMEA"), (d) Asia-Pacific and (e) Japan. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the plasma business. When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit. In fiscal 2016 , we used the income approach, specifically the discounted cash flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. We selected this method as being the most meaningful in preparing our goodwill assessments because the use of the income approach typically generates a more precise measurement of fair value than the market approach. Due to the increased adverse business conditions impacting multiple Haemonetics reporting units in fiscal 2016, we determined that a more precise measure of fair value was required when performing our goodwill impairment review compared to what was performed in prior years. In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our discounted cash flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our discounted cash flow analysis and reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk adjusted weighted average cost of capital ("WACC") as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test. In fiscal 2015 and 2014 , we determined the fair value of our reporting units based on the market approach. We utilized the market approach as we determined relevant comparable information was available, and accordingly such method was an appropriate alternative to the income method. Under the market approach, we estimated the fair value of our reporting units based on a combination of, a) market multiples of projected earnings before interest, taxes, depreciation and amortization (“EBITDA”) and b) market multiples of projected net revenues for each individual reporting unit. For the market approach, we used judgment in identifying the relevant comparable-company market multiples, such as recent divestitures/acquisitions, facts and circumstances surrounding the market and growth rates. Management assessed the relevance and reliability of the multiples by considering factors unique to its reporting units, including recent operating results, business plans, economic projections, anticipated future cash flows, and other data. EBITDA and revenue multiples were also significantly impacted by future growth opportunities for the reporting unit as well as for the company itself, general market and geographic sentiment, and pending or recently completed merger transactions. If the carrying value of a reporting unit exceeds its fair value, we perform the second step of the goodwill impairment test to measure the amount of impairment, if any. The second step compares the implied fair value of a reporting unit’s goodwill with its carrying value. To determine the implied fair value of goodwill, we allocate the fair value of a reporting unit to all of the assets and liabilities of that unit, including intangible assets, as if the reporting unit had been acquired in a business combination. Any excess of the value of a reporting unit over the amounts assigned to its assets and liabilities represents the implied fair value of goodwill. In the third quarter of fiscal 2016, we concluded that indicators of potential goodwill impairment were present for the EMEA and Americas Blood Center and Hospital reporting units, requiring an interim test. We recorded a preliminary impairment charge of $66.3 million in the EMEA reporting unit during the third quarter of fiscal 2016. During the fourth quarter of fiscal 2016, we completed our second step of the goodwill impairment test and concluded that no adjustment to the estimated $66.3 million impairment loss initially recorded was required, as there was significant intangible value attributed to customer relationships and developed technology based on the theoretical purchase price allocation. Refer to Note 5, Goodwill and Intangible Assets, for additional details regarding goodwill impairment. We review intangible assets subject to amortization for impairment at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. During fiscal 2016 , 2015 and 2014 , we determined that there were potential impairment indicators for certain intangible assets subject to amortization. As such, we performed the recoverability test described below for the relevant asset groups. In fiscal 2015 and 2014, we determined that the expected undiscounted cash flows exceeded the carrying value of the asset groups identified. In fiscal 2016, however, we determined that the undiscounted cash flows did not support the carrying value of the asset groups identified and, accordingly, recorded impairment charges of $25.8 million , of which $18.7 million related to the write down of the SOLX intangible assets and the remaining $7.1 million related to intangible assets that were identified as part of the Company's global strategic review. Refer to Note 5, Goodwill and Intangible Assets, for additional details regarding intangible asset impairments recorded. When an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified. We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group). If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life. Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed ASC Topic 985-20, Software , specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of five to 10 years . Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. We capitalize costs associated with both software that we sell as a separate product and software that is embedded in a device. We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. During the fourth quarter of fiscal 2016 , we recorded $6.0 million of impairment charges related to the discontinuance of certain capitalized software projects as a result of our global strategic review. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded. Other Current Liabilities Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were: (In thousands) April 2, March 28, VAT liabilities $ 1,289 $ 4,205 Forward contracts 4,210 2,657 Deferred revenue 27,053 22,362 Accrued taxes 3,876 3,819 All other 30,180 34,579 Total $ 66,608 $ 67,622 Other Long-Term Liabilities Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were: (In thousands) April 2, March 28, Unfunded pension liability 18,067 17,402 Unrecognized tax benefit 2,283 3,992 All other 5,756 10,343 Total $ 26,106 $ 31,737 Research and Development Expenses All research and development costs are expensed as incurred. Advertising Costs All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of (loss) income. Advertising expenses were $3.9 million , $4.5 million , and $3.6 million for 2016 , 2015 and 2014 , respectively. Accounting for Shipping and Handling Costs Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight. Income Taxes The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable. We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made when necessary. Tax reserves are reversed when the statute of limitations expires or the matter is considered effectively settled. We evaluate at the end of each reporting period whether some or all of the undistributed earnings of our foreign subsidiaries are permanently reinvested. We recognize deferred income tax liabilities to the extent that management asserts that undistributed earnings of its foreign subsidiaries are not permanently reinvested or will not be permanently reinvested in the future. Our position is based upon several factors including management’s evaluation of the Company and its subsidiaries’ financial requirements, the short term and long-term operational and fiscal objectives of the Company, and the tax consequences associated with the repatriation of earnings. Derivative Instruments We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes. When the underlying hedged transaction affects earnings, the gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other expense, net in our consolidated statements of (loss) income, depending on the nature of the underlying hedged transactions. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses of $1.4 million , $1.1 million , and $0.5 million in fiscal 2016 , 2015 and 2014 , respectively. On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815. Stock-Based Compensation We expense the fair value of stock-based awards granted to employees, board members and others, net of estimated forfeitures. To calculate the grant-date fair value of our stock options we use the Black-Scholes option-pricing model and for performance share units and market stock units we use Monte Carlo simulation models. Valuation of Acquisitions We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations

PRODUCT WARRANTIES

PRODUCT WARRANTIES	12 Months Ended
	Apr. 02, 2016
Product Warranties Disclosures [Abstract]
PRODUCT WARRANTIES	PRODUCT WARRANTIES We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary. (In thousands) April 2, March 28, Warranty accrual as of the beginning of the year $ 531 $ 590 Warranty provision 948 1,199 Warranty spending (1,059 ) (1,258 ) Warranty accrual as of the end of the year $ 420 $ 531

INVENTORIES

INVENTORIES	12 Months Ended
	Apr. 02, 2016
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. (In thousands) April 2, March 28, Raw materials $ 62,062 $ 71,794 Work-in-process 13,180 12,462 Finished goods 111,786 126,821 Total Inventories $ 187,028 $ 211,077 During the fourth quarter of fiscal 2016, we recorded $9.4 million of inventory charges and reserves, of which $5.3 million resulted from changes in demand for Blood Center products.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Apr. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill Impairment Testing and Charges Under ASC Topic 350, Intangibles - Goodwill and Other, goodwill and intangible assets determined to have indefinite useful lives are not amortized. Instead these assets are evaluated for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. Our reporting units for purposes of assessing goodwill impairment are the same as our operating segments, which are organized primarily based on geography and include: (a) North America Plasma, (b) Americas Blood Center and Hospital, (c) EMEA, (d) Asia-Pacific and (e) Japan. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the plasma business. During the third quarter of each fiscal year, we prepare our long term projections for net revenues, income and operating cash flows. The economic weakness in EMEA and declines in our U.S. blood center collections have negatively impacted earnings before interest, taxes, depreciation, and amortization ("EBITDA") and net revenues for our EMEA and Americas Blood Center and Hospital reporting units. Because of these market conditions and key uncertainties, including the market rate of adoption of our new products and the negative impact of intense competitive pressure on pricing and market share, we lowered our expectations in terms of the timing and amount of our future revenue, income and cash flows. As a result, we concluded in the third quarter of fiscal 2016 that indicators of potential goodwill impairment were present for the EMEA and Americas Blood Center and Hospital reporting units, therefore requiring an interim test for goodwill impairment. In accordance with ASC Topic 350, we prepared a “Step 1” Test that compared the estimated fair value of each reporting unit to its carrying value. We utilized a discounted cash flow approach in order to value our reporting units for the Step 1 Test, which required that we forecast future cash flows of the reporting units and discount the cash flow stream based upon a weighted average cost of capital that was derived, in part, from comparable companies within similar industries. The discounted cash flow calculations also included a terminal value calculation that was based upon an expected long-term growth rate for the applicable reporting unit. We believe that our procedures for estimating discounted future cash flows, including the terminal valuation, were reasonable and consistent with market conditions at the time of estimation. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test. The results of the Step 1 Test performed in the third quarter of fiscal 2016 indicated that the estimated fair value of all of our reporting units exceeded their respective carrying values, with the exception of EMEA, for which we recorded an estimated goodwill impairment charge, as discussed below. Based on this Step 1 analysis, the reporting unit that is most at risk of impairment in future periods is the Americas Blood Center and Hospital, which has an excess fair value over carrying value of approximately 25.8% and has allocated goodwill of $175.9 million . We believe that our assumptions used to determine the fair value of the Americas Blood Center and Hospital reporting unit were reasonable. If different assumptions were to be used, particularly with respect to estimating future cash flows, or if actual operating results and cash flows of the Americas Blood Center and Hospital differ from the estimated operating results and related cash flows, there is the potential that an impairment charge could result in future periods. Additionally, changes to the discount rate or the long-term growth rate could also give rise to an impairment in future periods. As a result of the carrying value of the EMEA reporting unit exceeding its estimated fair value, a "Step 2" Test was required for this reporting unit. The Step 2 Test measures the impairment loss by allocating the estimated fair value of the reporting unit, as determined in Step 1, to the reporting units’ assets and liabilities, with the residual amount representing the implied fair value of goodwill. To the extent the implied fair value of goodwill is less than the carrying value, an impairment loss is recognized. The Step 2 Test under ASC Topic 350 requires us to perform a theoretical purchase price allocation for the EMEA reporting unit to determine the implied fair value of goodwill as of the evaluation date. We finalized the Step 2 Test during the fourth quarter of fiscal 2016 and concluded no adjustment to the estimated $66.3 million impairment loss recorded in the third quarter of fiscal 2016 was required, as there was significant intangible value attributed to customer relationships and developed technology based on the theoretical purchase price allocation. The impairment charge recorded in the third quarter of fiscal 2016 represented the entire goodwill balance allocated to EMEA. This charge does not impact our liquidity, cash flows from operations, future operations, or compliance with debt covenants. The changes in the carrying amount of goodwill by reporting segment for fiscal 2016 and 2015 are as follows: (In thousands) Japan EMEA North America Plasma All Other Total Carrying amount as of March 29, 2014 $ 25,477 $ 74,019 $ 26,415 $ 210,857 $ 336,768 Currency translation (578 ) (1,324 ) — (556 ) (2,458 ) Carrying amount as of March 28, 2015 $ 24,899 $ 72,695 $ 26,415 $ 210,301 $ 334,310 Impairment charge — (66,305 ) — — (66,305 ) Transfer of goodwill between segments — (6,390 ) — 6,390 — Currency translation (16 ) — — (149 ) (165 ) Carrying amount as of April 2, 2016 $ 24,883 $ — $ 26,415 $ 216,542 $ 267,840 Intangible Asset Impairment In April 2013, we acquired a patented red cell storage solution, referred to as SOLX, from Hemerus Medical, LLC for cash consideration of $24.1 million plus an agreement to make certain future payments accounted for as contingent consideration. We acquired Hemerus to complement the portfolio of whole blood collection, filtration and processing product lines and to bring greater efficiency and productivity to whole blood collection and processing. During the third quarter of fiscal 2016 , we received U.S. Food and Drug Administration clearance for the SOLX solution with a Haemonetics whole blood filter. At that time, the vast majority of the U.S. market utilized a red cell filter, not a whole blood filter, for whole blood collection procedures as they seek to optimize blood component yield from each collection. To bring SOLX to market with a red cell filter would have required substantial additional investment. Accordingly, we conducted a final market review prior to proceeding with this investment, which indicated customers would not pay a price for a SOLX collection kit sufficient to recover the cost to produce it, or to provide an adequate return on the additional investment. As result, in fiscal 2016, we suspended further investment in the SOLX technology and recorded an impairment charge of $18.7 million to write down the carrying value of the SOLX intangible assets. In addition, we reversed the $4.9 million of contingent consideration liability we had recorded, as we do not expect to achieve the conditions that called for its payment. During the fourth quarter of fiscal 2016, we completed our global strategic review which resulted in the identification of certain intangible assets that were at risk of being impaired due to changes in the strategic direction of the Company. During the fourth quarter of fiscal 2016, we performed impairment tests for each of these asset groups and based on revised expectations, we recorded asset impairment charges of $7.1 million . Of the total $25.8 million of intangible asset impairments recorded during fiscal 2016, $6.6 million is recorded within cost of goods sold, while the remaining $19.2 million is included within impairment of assets on the consolidated statements of (loss) income. Of these intangible impairments, $6.6 million related to EMEA and the remaining $19.2 million related to our All Other operating segment. The gross carrying amount of intangible assets and the related accumulated amortization as of April 2, 2016 and March 28, 2015 is as follows: (In thousands) Gross Carrying Amount Accumulated Amortization (1) Net Weighted Average Useful Life (In years) As of April 2, 2016 Amortizable: Patents $ 8,545 $ 7,542 $ 1,003 9 Capitalized software 40,488 14,791 25,697 6 Other developed technology 126,142 73,475 52,667 12 Customer contracts and related relationships 196,085 89,804 106,281 10 Trade names 7,083 5,204 1,879 11 Total $ 378,343 $ 190,816 $ 187,527 10 Non-amortizable: In-process software development $ 14,427 In-process patents 2,504 Total $ 16,931 (1) Includes impairment of SOLX and other intangible assets, as discussed below. (In thousands) Gross Carrying Amount Accumulated Amortization Net Weighted Average Useful Life (In years) As of March 28, 2015 Amortizable: Patents $ 7,686 $ 7,373 $ 313 9 Capitalized software 31,818 5,654 26,164 7 Other developed technology 124,573 46,474 78,099 12 Customer contracts and related relationships 195,985 70,440 125,545 10 Trade names 7,042 3,234 3,808 11 Total $ 367,104 $ 133,175 $ 233,929 10 Non-amortizable: In-process software development $ 7,872 In-process patents 2,787 Total $ 10,659 Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are 2 to 19 years. The changes to the net carrying value of our intangible assets from March 28, 2015 to April 2, 2016 reflect the impact of the SOLX impairment discussed above as well as the additional intangible asset impairments recorded during the fourth quarter of fiscal 2016 totaling $7.1 million , as discussed above. Of the $7.1 million of impairments recorded during the fourth quarter of fiscal 2016, approximately $6.0 million was related to the discontinuance of certain capitalized software projects as discussed in Note 16, Capitalization of Software Development Costs . Amortization expense, partially offset by the investment in capitalized software and other less significant intangible assets, also contributed to the change in net carrying value. Aggregate amortization expense for amortized intangible assets for fiscal 2016 was $59.3 million , which included $25.4 million of amortization expense as a result of the intangible asset impairments discussed above. Fiscal 2015 and 2014 amortization expense was $33.5 million and $29.2 million , respectively. Future annual amortization expense on intangible assets is estimated to be as follows: Fiscal Year Amount (in thousands) 2017 $ 31,397 2018 $ 30,959 2019 $ 29,250 2020 $ 27,353 2021 $ 25,512

DERIVATIVES AND FAIR VALUE MEAS

DERIVATIVES AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Apr. 02, 2016
Derivatives and Fair Value Measurements [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	DERIVATIVES AND FAIR VALUE MEASUREMENTS We manufacture, market and sell our products globally. For the fiscal year ended April 2, 2016 , 42.9% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, British Pound Sterling, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. Designated Foreign Currency Hedge Contracts All of our designated foreign currency hedge contracts as of April 2, 2016 and March 28, 2015 were cash flow hedges under ASC Topic 815, Derivatives and Hedging . We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive (loss) income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $107.4 million as of April 2, 2016 and $145.8 million as of March 28, 2015 . During fiscal 2016 , we recognized net gains of $8.8 million in earnings on our cash flow hedges, compared to recognized net gains of $6.5 million and $8.6 million during fiscal 2015 and 2014 , respectively. For the fiscal year ended April 2, 2016 , a $3.9 million loss, net of tax, was recorded in accumulated other comprehensive (loss) income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to a gain of $12.2 million , net of tax, for the fiscal year ended March 28, 2015 and a gain of $3.7 million , net of tax, for the fiscal year ended March 29, 2014 . At April 2, 2016 , losses of $3.9 million , net of tax, will be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of April 2, 2016 mature within twelve months. Non-Designated Foreign Currency Contracts We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $48.8 million as of April 2, 2016 and $52.6 million as of March 28, 2015 . Interest Rate Swaps On August 1, 2012 , we entered into a credit agreement, as amended June 30, 2014, which provided for a term loan ("Credit Agreement"). Under the terms of this Credit Agreement, we may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, we have chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16 th of 1% (“Adjusted LIBOR ”). The terms of the Credit Agreement allow us to borrow in multiple tranches. Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR . Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. We formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception to ensure that our interest rate swaps qualify for hedge accounting. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote. On December 21, 2012 , we entered into two interest rate swap agreements (the "Swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional value of $250.0 million of debt. The Swaps mature on August 1, 2017 . We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For the fiscal year ended April 2, 2016 , an insignificant gain was recorded in Accumulated Other Comprehensive (Loss) Income to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges. For fiscal years ended March 28, 2015 and March 29, 2014 , a loss of $0.9 million and a gain of $1.3 million , respectively, net of tax, were recorded in Accumulated Other Comprehensive (Loss) Income for this effective portion. Fair Value of Derivative Instruments The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of (loss) income and comprehensive (loss) income for the fiscal year ended April 2, 2016 . Derivative Instruments Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive (Loss) Income Amount of Gain Reclassified from Accumulated Other Comprehensive (Loss) Income into Earnings Location in Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income Amount of Gain (Loss) Excluded from Testing (*) Location in Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (In thousands) Designated foreign currency hedge contracts, net of tax $ (3,940 ) $ 8,822 Net revenues, COGS, and SG&A $ 102 Other expense, net Non-designated foreign currency hedge contracts — — $ (203 ) Other expense, net Designated interest rate swaps, net of tax $ 2 $ — Other expense, net $ — (*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing. We did not have fair value hedges or net investment hedges outstanding as of April 2, 2016 or March 28, 2015 . As of April 2, 2016 , the amount recognized as a deferred tax asset for designated foreign currency hedges was $0.3 million . ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures , by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of April 2, 2016 , we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments. The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets: (In thousands) Location in Balance Sheet Balance as of April 2, 2016 Balance as of March 28, 2015 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 427 $ 9,740 Designated interest rate swaps Other current assets — — $ 427 $ 9,740 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 4,056 $ 2,499 Designated interest rate swaps Other current liabilities 154 159 $ 4,210 $ 2,658 Other Fair Value Measurements ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal years ended April 2, 2016 and March 28, 2015 , we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following: As of April 2, 2016 Level 1 Level 2 Level 3 Total (In thousands) Assets Money market funds $ 72,491 $ — $ — $ 72,491 Designated foreign currency hedge contracts — 427 — 427 $ 72,491 $ 427 $ — $ 72,918 Liabilities Designated foreign currency hedge contracts $ — $ 4,056 $ — $ 4,056 Designated interest rate swaps — 154 — 154 Contingent consideration — — — — $ — $ 4,210 $ — $ 4,210 As of March 28, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets Money market funds $ 119,946 $ — $ — $ 119,946 Designated foreign currency hedge contracts — 9,740 — 9,740 $ 119,946 $ 9,740 $ — $ 129,686 Liabilities Forward currency hedge contracts $ — $ 2,499 $ — $ 2,499 Designated interest rate swaps — 159 — 159 Contingent consideration — — 4,727 4,727 $ — $ 2,658 $ 4,727 $ 7,385 For the fiscal years ended April 2, 2016 and March 28, 2015 , non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above tables. Contingent consideration Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period. Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets. The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the year ended April 2, 2016 . (In thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at March 28, 2015 $ 4,727 Fair value adjustment (4,727 ) Balance at April 2, 2016 $ — As discussed in Note 5, Goodwill and Intangible Assets , during fiscal 2016 , we reversed the remaining $4.9 million of contingent consideration liability associated with the SOLX asset, as we do not expect to achieve the conditions that called for its payment. This reversal, as well as the fair value adjustment recorded earlier in fiscal 2016 , are included within the contingent consideration (income) expense line on the consolidated statements of (loss) income for fiscal 2016 . Other Fair Value Disclosures The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value. Details pertaining to the Term Loan can be found in Note 7, Notes Payable and Long-Term Debt .

NOTES PAYABLE AND LONG-TERM DEB

NOTES PAYABLE AND LONG-TERM DEBT	12 Months Ended
	Apr. 02, 2016
Debt Disclosure [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	NOTES PAYABLE AND LONG-TERM DEBT Notes payable and long-term debt consisted of the following: (In thousands) April 2, 2016 March 28, 2015 Term loan, net of financing fees $ 406,175 $ 426,814 Real estate mortgage — 851 Bank loans and other borrowings 1,825 226 Less current portion (43,471 ) (21,522 ) Long-term debt $ 364,529 $ 406,369 On August 1, 2012 , we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million term loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and matured on August 1, 2017 . Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc . From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16 th of 1%. The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. The Company currently borrows in four tranches. Interest for the Credit Facilities was based on Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of leverage ratios and customary credit terms which included financial and negative covenants. Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. The current margin of the Term Loan is 1.375% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was approximately 1.9% as of April 2, 2016 . The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed. On June 30, 2014 , we modified our existing Credit Facilities by extending the maturity date to July 1, 2019 , extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million Revolving Credit Facility and establishes interest rates in the range of LIBOR plus 1.125% to 1.500% depending on certain conditions. At April 2, 2016 , $358.1 million was outstanding under the Term Loan and $50.0 million was outstanding on the Revolving Credit Facility, both with an interest rate of 1.875% . No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $408.1 million as of April 2, 2016 . Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0 :1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0 :1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities. The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement. Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of April 2, 2016 , we were in compliance with the covenants. The goodwill and intangible asset impairment charges discussed in Note 5, Goodwill and Intangible Assets, and the property, plant and equipment impairment charges discussed in Note 12, Property Plant and Equipment , are excluded from the definition of Consolidated EBITDA in the Credit Agreement. Commitment fee Pursuant to the Credit Agreement we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300% . The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.250% . Debt issuance costs and interest Expenses associated with the issuance of the Term Loan were capitalized and are amortized to interest expense over the life of the term loan using the effective interest method. As of April 2, 2016, the $408.1 million term loan balance was netted down by the $1.9 million of remaining debt discount, resulting in a net note payable of $406.2 million . Interest expense was $8.5 million for both the fiscal years ended April 2, 2016 and March 28, 2015 , respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying consolidated balance sheets. As of April 2, 2016 , accrued interest totaled $0.1 million . Other Credit Facilities Other debt as of April 2, 2016 includes short term bank borrowings of $1.8 million under operating lines of credit. In December 2000 , we entered into a $10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement required principal and interest payments of $0.1 million per month for a period of 180 months , commencing February 1, 2001. This Mortgage Agreement was repaid in full during fiscal 2016. Maturity Profile The maturity profile of all gross long-term debt, exclusive of debt discounts, as of April 2, 2016 is presented below: Fiscal year (in thousands) Credit Facilities Bank loans and other borrowings Total 2017 $ 42,683 $ 154 $ 42,837 2018 45,054 108 45,162 2019 151,763 89 151,852 2020 168,564 50 168,614 $ 408,064 $ 401 $ 408,465

INCOME TAXES

INCOME TAXES	12 Months Ended
	Apr. 02, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Domestic and foreign income before provision for income tax is as follows: (In thousands) April 2, March 28, March 29, Domestic $ (18,526 ) $ (17,265 ) $ (6,859 ) Foreign (34,890 ) 48,430 43,260 Total $ (53,416 ) $ 31,165 $ 36,401 The income tax provision from continuing operations contains the following components: (In thousands) April 2, March 28, March 29, Current Federal $ 12 $ 3,526 $ (4,896 ) State (660 ) 898 873 Foreign 3,842 5,614 5,478 Total current $ 3,194 $ 10,038 $ 1,455 Deferred Federal 3,532 1,227 (1,785 ) State 319 3,215 207 Foreign (4,882 ) (212 ) 1,376 Total deferred $ (1,031 ) $ 4,230 $ (202 ) Total $ 2,163 $ 14,268 $ 1,253 Our subsidiary in Puerto Rico has been granted a fifteen year tax grant which expires in 2027. Our qualification for the tax grant is dependent on the continuation of our manufacturing activities in Puerto Rico. We benefit from a reduced tax rate on our earnings in Puerto Rico under the tax grant. Our subsidiary in Switzerland operates as a principal company for direct federal tax purposes. Operating under this structure affords our Swiss subsidiary a reduced tax rate in Switzerland. Our Swiss subsidiary also operates under a 10 year tax holiday set to expire in 2018. In fiscal 2016 , we recorded a $7.1 million benefit to income taxes relating to the impairment of goodwill and certain intangible assets. Tax affected, significant temporary differences comprising the net deferred tax liability are as follows: (In thousands) April 2, March 28, Deferred tax assets: Depreciation $ 1,749 $ 609 Amortization of intangibles 4,417 727 Inventory 7,607 6,193 Hedging 382 84 Accruals, reserves and other deferred tax assets 12,590 17,526 Net operating loss carry-forward 13,484 5,392 Stock based compensation 9,622 10,652 Tax credit carry-forward, net 16,191 8,678 Gross deferred tax assets 66,042 49,861 Less valuation allowance (24,297 ) (16,027 ) Total deferred tax assets (after valuation allowance) 41,745 33,834 Deferred tax liabilities: Depreciation (28,972 ) (24,342 ) Amortization of goodwill and intangibles (23,626 ) (24,764 ) Unremitted earnings (700 ) — Other deferred tax liabilities (2,769 ) (1,604 ) Total deferred tax liabilities (56,067 ) (50,710 ) Net deferred tax liabilities $ (14,322 ) $ (16,876 ) The valuation allowance increased by $8.3 million during 2016 , primarily as the result of current year net operating losses and tax credits generated in domestic and foreign jurisdictions in which we have concluded that our deferred tax assets are not more-likely-than-not realizable. In determining the need for a valuation allowance, we have assessed the available means of recovering deferred tax assets, including the ability to carryback net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. We have also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets. We believe we are able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence. The worldwide net deferred tax liability as of April 2, 2016 includes deferred tax liabilities related to amortizable tax basis in goodwill, which are indefinite lived and are not considered to be a source of taxable income. As of April 2, 2016 , we maintain a valuation allowance against the portion of our U.S. net deferred tax assets that are not more-likely-than-not realizable and a full valuation allowance against the net deferred tax assets of certain foreign subsidiaries. At April 2, 2016 , we have U.S. federal net operating loss carry-forwards of approximately $29.2 million , U.S. state net operating loss carry-forwards of $33.1 million , federal tax credit carry-forwards of $13.7 million and state tax credit carry-forwards of $3.8 million that are available to reduce future taxable income. A portion of the federal net operating losses are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 382. Certain of the aforementioned amounts have not been recognized because they relate to excess stock based compensation. At April 2, 2016 , $4.0 million of the federal net operating loss carry-forwards, $5.3 million of the state net operating loss carry-forwards, none of the federal tax credit carry-forwards and none of the state tax credit carry-forwards relate to excess stock based compensation tax deductions for which the benefit will be recorded to additional paid-in capital when recognized. The federal and state net operating losses begin to expire in 2022 and 2019, respectively. The federal and state tax credits begin to expire in 2023 and 2025, respectively. As of April 2, 2016 , we have foreign net operating losses of approximately $25.2 million that are available to reduce future income, of which $12.2 million would expire in 2023 and $0.1 million would expire in 2025, with the remaining foreign net operating losses having unlimited carryforward. As of April 2, 2016, we have provided $0.7 million of U.S. deferred taxes on approximately $5.4 million of unremitted earnings which are not indefinitely reinvested. Of this amount, $0.3 million affected the Company's effective tax rate in fiscal 2016. We have not provided U.S. deferred income taxes or foreign withholding taxes on unremitted earnings of foreign subsidiaries of approximately $254.1 million as such amounts are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as our subsidiaries continue to expand their operations, to service existing debt obligations and to fund future foreign acquisitions. We do not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations. The income tax provision from continuing operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following: (In thousands) April 2, March 28, March 29, Tax at federal statutory rate $ (18,695 ) 35.0 % $ 10,907 35.0 % $ 12,739 35.0 % Difference between U.S. and foreign tax 10,645 (19.9 )% (6,929 ) (22.2 )% (10,846 ) (29.8 )% State income taxes net of federal benefit 134 (0.3 )% (818 ) (2.6 )% (252 ) (0.7 )% Change in uncertain tax positions (1,820 ) 3.4 % (1,762 ) (5.7 )% (1,678 ) (4.6 )% Intercompany loan deduction — — % — — % (2,185 ) (6.0 )% Unremitted earnings 735 (1.4 )% — — % — — % Deferred statutory rate changes (2,653 ) 5.0 % — — % — — % Non-deductible goodwill impairment 2,861 (5.4 )% — — % — — % Non-deductible expenses 1,491 (2.8 )% 1,237 4.0 % 1,035 2.8 % Research credits (672 ) 1.3 % (1,000 ) (3.2 )% (688 ) (1.9 )% Tax amortization of goodwill 4,185 (7.8 )% 3,826 12.3 % — — % Valuation allowance 5,194 (9.7 )% 8,524 27.4 % 2,400 6.6 % Other, net 758 (1.4 )% 283 0.8 % 728 2.0 % Income tax provision $ 2,163 (4.0 )% $ 14,268 45.8 % $ 1,253 3.4 % We recorded an income tax provision of $2.2 million , representing an effective tax rate of (4)% . The effective tax rate of (4)% differs from the U.S. statutory rate of 35.0% primarily as a result of the jurisdictional mix of earnings and losses generated in the U.S. and certain foreign subsidiaries that have a valuation allowance and therefore cannot be benefited. Other significant items impacting the rate include the tax provision related to the amortization of U.S. goodwill for tax purposes which gives rise to an indefinite lived deferred tax liability, a tax benefit related to deferred tax rate changes primarily associated with the decrease in the statutory rate applied to the deferred tax liability associated with goodwill for our Puerto Rico subsidiary and releases of tax reserves for uncertain tax positions. During the current year we changed our indefinite reinvestment assertion with respect to a portion of the unremitted earnings of our foreign subsidiaries. We have recorded a $0.3 million tax provision associated with the portion of unremitted foreign earnings that are not considered indefinitely reinvested. Unrecognized Tax Benefits Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of April 2, 2016 , we had $2.5 million of unrecognized tax benefits, of which $0.6 million would impact the effective tax rate, if recognized. As of March 28, 2015 , we had $7.1 million of unrecognized tax benefits, of which $2.0 million would impact the effective tax rate, if recognized. At March 29, 2014 , we had $5.6 million of unrecognized tax benefits, all of which would impact the effective tax rate, if recognized. During the fiscal year ended April 2, 2016 our unrecognized tax benefits were decreased by $4.5 million primarily due to the release of certain previously established reserves as a result of accounting method changes that were filed during the year, as well as the release of other reserves as a result of the closure of tax statutes of limitations. The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended April 2, 2016 , March 28, 2015 and March 29, 2014 : (In thousands) April 2, March 28, March 29, Beginning Balance $ 7,070 $ 5,604 $ 6,930 Additions based upon positions related to the current year — — — Additions for tax positions of prior years 340 3,234 990 Reductions of tax positions (4,158 ) — — Settlements with taxing authorities — (338 ) — Closure of statute of limitations (729 ) (1,430 ) (2,316 ) Ending Balance $ 2,523 $ 7,070 $ 5,604 As of April 2, 2016 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $0.4 million in the next twelve months, as a result of closure of various statutes of limitations. Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $0.4 million and $0.7 million of gross interest and penalties were accrued at April 2, 2016 and March 28, 2015 , respectively and is not included in the amounts above. There was a benefit included in tax expense associated with accrued interest and penalties of $0.3 million , $0.3 million and zero for the periods ended April 2, 2016 , March 28, 2015 and March 29, 2014 , respectively. We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions, we are no longer subject to U.S. federal, state, or local income tax examinations for years before 2012 and foreign income tax examinations for years before 2011.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Apr. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2026 . Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes. Approximate future basic rental commitments under operating leases as of April 2, 2016 are as follows: Fiscal Year Ending (In thousands) 2017 $ 4,845 2018 3,830 2019 2,476 2020 1,820 2021 1,708 Thereafter 6,143 $ 20,822 Rent expense in fiscal 2016 , 2015 , and 2014 was $6.8 million , $6.3 million and $7.7 million , respectively. Some of the Company's operating leases include renewal provisions, escalation clauses and options to purchase the facilities that we lease. We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations. Italian Employment Litigation Our Italian manufacturing subsidiary is party to several actions initiated by employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift. In addition, a union represented in the Ascoli plant has filed an action claiming that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings. Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment. As of April 2, 2016 , the total amount of damages claimed by the plaintiffs in these matters is approximately $4.6 million . It is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses and therefore no amounts have been accrued. We may receive other, similar claims in the future.

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Apr. 02, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
CAPITAL STOCK	CAPITAL STOCK Stock Plans The 2005 Long-Term Incentive Compensation Plan (the “2005 Incentive Compensation Plan”) permits the award of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors. The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 19,824,920 . The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000 . Any shares that are subject to the award of stock options shall be counted against this limit as one (1) share for every one (1) share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.02 shares for every one (1) share granted. The total shares available for future grant as of April 2, 2016 was 6,037,933 . Stock-Based Compensation Compensation cost related to stock-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of stock-based compensation expense, which is recorded on a straight line basis, was as follows: (In thousands) 2016 2015 2014 Selling, general and administrative expenses $5,183 $11,251 $10,507 Research and development 1,060 1,706 1,545 Cost of goods sold 706 1,138 1,030 $6,949 $14,095 $13,082 We did no t recognize an income tax benefit associated with our stock-based compensation arrangements for the fiscal year ended April 2, 2016 . We recognized an income tax benefit associated with our stock-based compensation arrangements of $4.5 million and $4.3 million for the fiscal years ended March 28, 2015 and March 29, 2014 , respectively. There was no excess cash tax benefit classified as a financing cash inflow in fiscal 2016 and the excess cash tax benefit classified as a financing cash inflow in fiscal 2015 and 2014 was $1.6 million and $2.4 million , respectively. Stock Options Options are granted to purchase ordinary shares at prices as determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options generally vest in equal installments over a four year period for employees and one year from grant for non-employee directors. Options expire not more than 7 years from the date of the grant. The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience. A summary of stock option activity for the fiscal year ended April 2, 2016 is as follows: Options Outstanding (shares) Weighted Average Exercise Price per Share Weighted Average Remaining Life (years) Aggregate Intrinsic Value ($000’s) Outstanding at March 28, 2015 3,761,666 $ 33.90 4.02 $ 37,067 Granted 409,047 32.50 Exercised (491,546 ) 28.55 Forfeited/Canceled (727,984 ) 37.98 Outstanding at April 2, 2016 2,951,183 $ 33.59 3.34 $ 9,684 Exercisable at April 2, 2016 2,288,166 $ 33.22 2.59 $ 8,428 Vested or expected to vest at April 2, 2016 2,847,285 $ 33.56 3.21 $ 9,432 The total intrinsic value of options exercised was $4.5 million , $5.6 million , and $11.7 million during fiscal 2016 , 2015 , and 2014 , respectively. As of April 2, 2016 , there was $4.5 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.83 years. The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock over the expected term of the option. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period. The assumptions utilized for option grants during the periods presented are as follows: April 2, March 28, March 29, Volatility 22.8 % 22.5 % 24.8 % Expected life (years) 4.9 4.9 4.9 Risk-free interest rate 1.4 % 1.5 % 1.3 % Dividend yield 0.0 % 0.0 % 0.0 % Fair value per option $ 7.40 $ 7.91 $ 10.15 Restricted Stock Units Restricted Stock Units ("RSUs") generally vest in equal installments over a four year period for employees and one year from grant for non-employee directors. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant. A summary of RSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 357,547 $ 36.73 Granted 278,260 33.19 Vested (112,333 ) 36.07 Forfeited (142,603 ) 36.72 Unvested at April 2, 2016 380,871 $ 34.33 The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows: (In thousands, except per share data) April 2, March 28, March 29, Grant-date fair value per RSU $ 33.19 $ 34.89 $ 42.24 Fair value of RSUs vested $ 36.07 $ 36.62 $ 32.70 As of April 2, 2016 , there was $9.5 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.46 years. Performance Stock Units The grant date fair value of Performance Stock Units ("PSUs"), adjusted for estimated forfeitures, is recognized as expense on a straight line basis from the grant date through the end of the performance period. The value of these PSUs is based on relative shareholder return (total shareholder return for the Company as compared to total shareholder return of the PSU peer group), measured over a three year performance period. The PSU peer group consists of companies comprising the Standard & Poor's Health Care Equipment Index (the "Index"). Depending on the Company's relative performance during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200% , of the award granted. As a result, we may issue up to 204,672 shares related to these awards. If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100% of the target award, regardless of the Company's performance relative to the Index. A summary of PSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 129,130 $ 35.09 Granted 80,145 29.20 Vested — — Forfeited (106,939 ) 34.22 Unvested at April 2, 2016 102,336 $ 31.38 The Company uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards. The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows: April 2, March 28, Expected stock price volatility 22.27 % 20.08 % Peer group stock price volatility 31.95 % 31.52 % Correlation of returns 26.27 % 30.52 % The weighted-average grant-date fair value of PSUs granted was $29.20 and $35.09 in fiscal 2016 and 2015, respectively. As of April 2, 2016 , there was $2.7 million of total unrecognized compensation cost related to non-vested performance share units. This cost is expected to be recognized over a weighted average period of 2.21 years. Market Stock Units The grant date fair value of Market Stock Units ("MSUs"), adjusted for estimated forfeitures, is recognized as expense on a straight line basis from the grant date through the end of the performance period. The value of these MSUs is based the performance of Haemonetics’ stock through March 31, 2017. If Haemonetics' stock is below a minimum threshold price of $50 per share during the relevant measurement period, the holders receive no market share units. If the stock achieves certain price levels, the holders are eligible to receive up to three times the “target” amount of market share units. As a result, we may issue up to 458,904 shares at a stock price of $85 per share or higher in connection with these grants. A summary of MSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 287,682 $ 33.90 Granted 33,550 10.21 Vested — — Forfeited (168,264 ) 37.42 Unvested at April 2, 2016 152,968 $ 24.84 The Company uses the Monte Carlo model to determine the fair value of each market stock unit. The assumptions used in the Monte Carlo model for MSUs granted during each year were as follows: April 2, March 28, March 29, Volatility 24.0 % 21.2 % 20.2 % Expected life (years) 1.7 2.8 3.7 Risk-free interest rate 0.5 % 0.8 % 0.9 % Dividend yield 0.0 % 0.0 % 0.0 % The weighted-average grant-date fair value of MSUs granted was $10.21 , $7.44 and $36.36 in fiscal 2016, 2015 and 2014, respectively. As of April 2, 2016 , there was $1.8 million of total unrecognized compensation cost related to non-vested market stock units. This cost is expected to be recognized over a weighted average period of 1.0 years. Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 1,400,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan. The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% or more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period. The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions: April 2, March 28, March 29, Volatility 21.1 % 23.7 % 22.9 % Expected life (months) 6 6 6 Risk-free interest rate 0.2 % 0.1 % 0.1 % Dividend Yield 0.0 % 0.0 % 0.0 % The weighted average grant date fair value of the six -month option inherent in the Purchase Plan was approximately $7.80 , $7.09 , and $8.25 during fiscal 2016 , 2015 , and 2014 , respectively.

EARNINGS PER SHARE ("EPS")

EARNINGS PER SHARE ("EPS")	12 Months Ended
	Apr. 02, 2016
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. (In thousands, except per share amounts) April 2, March 28, March 29, Basic EPS Net (loss) income $ (55,579 ) $ 16,897 $ 35,148 Weighted average shares 50,910 51,533 51,611 Basic (loss) income per share $ (1.09 ) $ 0.33 $ 0.68 Diluted EPS Net (loss) income $ (55,579 ) $ 16,897 $ 35,148 Basic weighted average shares 50,910 51,533 51,611 Net effect of common stock equivalents — 556 766 Diluted weighted average shares 50,910 52,089 52,377 Diluted (loss) income per share $ (1.09 ) $ 0.32 $ 0.67 Basic earnings per share is calculated using our weighted-average outstanding common shares. Diluted earnings per share is calculated using our weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For fiscal 2016 , we recognized a net loss; therefore we excluded the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect. Weighted average shares outstanding, assuming dilution, excludes the impact of 1.6 million and 1.1 million stock options and restricted share units for fiscal years 2015 and 2014 , respectively, because these securities were anti-dilutive during the noted periods.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Apr. 02, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property and equipment consisted of the following: (In thousands) April 2, 2016 March 28, 2015 Land $ 7,905 $ 9,468 Building and building improvements 117,132 118,384 Plant equipment and machinery 238,549 220,793 Office equipment and information technology 127,019 118,810 Haemonetics equipment 295,853 264,307 Total 786,458 731,762 Less: accumulated depreciation and amortization (448,824 ) (409,814 ) Property, plant and equipment, net $ 337,634 $ 321,948 During fiscal 2016, we impaired $9.1 million of property, plant and equipment as a result of our global strategic review, of which $6.9 million was included within impairment of assets on the consolidated statements of (loss) income and the remaining $2.2 million was included within cost of goods sold. Approximately $3.0 million of the property, plant and equipment impairment was the result of the write down to fair value of certain land, buildings and related equipment in connection with its reclassification to assets held for sale, as discussed below. We determined the fair value of these assets using a probability weighted average cash flow method. This impairment impacted our EMEA segment, while the remaining $6.1 million related to our All Other segment. Depreciation expense of $56.8 million in fiscal 2016 , includes $0.8 million of additional depreciation expense due to asset impairments during the period related to assets that were previously place in service. Depreciation expense was $52.6 million for both fiscal 2015 and 2014 . Assets Held for Sale We periodically review long-lived assets against our plan to retain or ultimately dispose of properties and equipment. If we decide to dispose of a property or equipment, it will be moved to assets held for sale and actively marketed. We analyze market conditions each reporting period and record additional impairments due to declines in market values of like assets. The fair value of the property is determined by observable inputs such as appraisals and prices of comparable properties in active markets for assets like ours. Gains are not recognized until the properties are sold. Assets held for sale includes land, buildings and related equipment for properties we plan to dispose of. The assets are valued at the lower of net depreciable value or net realizable value. At April 2, 2016 , we have one property and related equipment totaling $1.7 million that we have reclassified to assets held for sale. This amount is included within other current assets on our consolidated balance sheet.

RETIREMENT PLANS

RETIREMENT PLANS	12 Months Ended
	Apr. 02, 2016
Compensation and Retirement Disclosure [Abstract]
RETIREMENT PLANS	RETIREMENT PLANS Defined Contribution Plans We have a Savings Plus Plan (the "Plan") that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $5.4 million , $5.8 million , and $6.2 million in fiscal 2016, 2015, and 2014 , respectively. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Plan in fiscal 2016 , 2015 , or 2014 . Some of our subsidiaries also have defined contribution plans, to which both the employee and the employer make contributions. The employer contributions to these plans totaled $0.8 million , $1.0 million , and $0.8 million in fiscal 2016 , 2015 , and 2014 , respectively. Defined Benefit Plans ASC Topic 715, Compensation — Retirement Benefits , requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive (loss) income on its Statement of Stockholders’ Equity and Comprehensive (Loss) Income. Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change. Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components: (In thousands) 2016 2015 2014 Service cost $ 3,560 $ 2,979 $ 3,351 Interest cost on benefit obligation 371 686 623 Expected (return)/loss on plan assets (330 ) (449 ) (435 ) Actuarial loss/(gain) 598 107 88 Amortization of unrecognized prior service cost (38 ) (29 ) 182 Amortization of unrecognized transition obligation 42 45 47 Totals $ 4,203 $ 3,339 $ 3,856 The activity under those defined benefit plans are as follows: (In thousands) April 2, March 28, Change in Benefit Obligation: Benefit Obligation, beginning of year $ (40,567 ) $ (32,621 ) Service cost (3,560 ) (2,979 ) Interest cost (371 ) (686 ) Benefits paid 3,780 4,902 Actuarial (loss)/gain 424 (6,883 ) Employee and plan participants contribution (1,839 ) (2,978 ) Plan Amendments 833 114 Foreign currency changes 3,381 564 Benefit obligation, end of year $ (37,919 ) $ (40,567 ) Change in Plan Assets: Fair value of plan assets, beginning of year $ 23,165 $ 19,981 Company contributions 1,987 2,112 Benefits paid (3,779 ) (4,621 ) Gain/(Loss) on plan assets 446 506 Employee and plan participants contributions 1,861 2,851 Foreign currency changes (3,828 ) 2,336 Fair value of Plan Assets, end of year $ 19,852 $ 23,165 Funded Status* $ (18,067 ) $ (17,402 ) Unrecognized net actuarial loss/(gain) 10,168 11,096 Unrecognized initial obligation 37 64 Unrecognized prior service cost (1,186 ) (459 ) Net amount recognized $ (9,048 ) $ (6,701 ) * The unfunded status is all non-current. One of the benefit plans is funded by benefit payments made by the Company. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $8.7 million and $9.2 million as of April 2, 2016 and March 28, 2015 , respectively. The accumulated benefit obligation for all plans was $36.4 million and $34.9 million for the fiscal year ended April 2, 2016 and March 28, 2015 , respectively. There were no plans where the plan assets were greater than the accumulated benefit obligation as of April 2, 2016 and March 28, 2015 . The components of the change recorded in our accumulated other comprehensive (loss) income related to our defined benefit plans, net of tax, are as follows (in thousands): Balance, March 30, 2013 $ (5,073 ) Obligation at transition 172 Actuarial loss (129 ) Prior service cost 438 Balance as of March 29, 2014 $ (4,592 ) Obligation at transition (19 ) Actuarial loss (6,198 ) Prior service cost 1,886 Balance as of March 28, 2015 $ (8,923 ) Obligation at transition 33 Actuarial loss 681 Prior service cost 717 Balance as of April 2, 2016 $ (7,492 ) We expect to amortize $0.2 million from accumulated other comprehensive loss to net periodic benefit cost during 2017 . The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows: April 2, March 28, March 29, Discount rate 0.72 % 0.93 % 2.02 % Rate of increased salary levels 1.58 % 1.65 % 1.57 % Expected long-term rate of return on assets 1.20 % 1.68 % 1.94 % Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets. We have no other material obligation for post-retirement or post-employment benefits. Our investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements. ASC Topic 820, Fair Value Measurements and Disclosures , provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of April 2, 2016 . Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 6, Derivatives and Fair Value Measurements , all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts. Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at April 2, 2016 . Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments are as follows: (in thousands) Fiscal Year 2017 $ 1,746 Fiscal Year 2018 1,542 Fiscal Year 2019 1,523 Fiscal Year 2020 1,883 Fiscal Year 2021 1,687 Fiscal Year 2022-2026 7,872 $ 16,253 The Company's contributions for fiscal 2017 are expected to be consistent with the current year.

SEGMENT AND ENTERPRISE-WIDE INF

SEGMENT AND ENTERPRISE-WIDE INFORMATION	12 Months Ended
	Apr. 02, 2016
Segment Reporting [Abstract]
SEGMENT AND ENTERPRISE-WIDE INFORMATION	SEGMENT AND ENTERPRISE-WIDE INFORMATION We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the plasma business. We aggregate components within an operating segment that have similar economic characteristics. In prior periods, the Company believed a single reportable segment was consistent with its basic organizational structure and believed aggregation was consistent with its primary basis for decision making. As a result, prior year segment information has been restated to conform to fiscal 2016 's reportable segments. The Company’s reportable segments are as follows: • Japan • Europe, Middle East and Africa (collectively “EMEA”) • North America Plasma • All Other The Company has aggregated the following two operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin: • Americas Blood Center and Hospital • Asia - Pacific Management measures and evaluates the Company’s operating segments based on operating margin. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and transformation costs, deal amortization, impairments and other (income)/expense associated with certain acquisitions. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Segment assets have not been presented since management does not evaluate the Company’s operating segments using this information. Further, management measures and evaluates the Company's net revenues and operating income on a constant currency basis, therefore segment information is presented on a constant currency basis. Selected information by business segment is presented below: (In thousands) April 2, March 28, March 29, Net revenues Japan $ 84,270 $ 83,547 $ 89,041 EMEA 175,874 183,753 193,691 North America Plasma 279,803 240,705 213,215 All Other 370,568 375,827 400,133 Net revenues (constant currency) 910,515 883,832 896,080 Effect of exchange rates (1,683 ) 26,541 42,429 Net revenues (reported) $ 908,832 $ 910,373 $ 938,509 (In thousands) April 2, March 28, March 29, Segment operating income Japan $ 37,165 $ 36,843 $ 38,685 EMEA 36,976 44,998 49,373 North America Plasma 100,367 89,092 82,497 All Other 135,580 142,531 154,099 Segment operating income (constant currency) 310,088 313,464 324,654 Corporate operating expenses (constant currency) (194,361 ) (189,867 ) (186,562 ) Non-GAAP operating income (constant currency) 115,727 123,597 138,092 Effect of exchange rates 3,977 13,906 21,147 Non-GAAP operating income (reported) 119,704 137,503 159,239 Unallocated amounts Restructuring and transformation costs 42,185 69,697 84,706 Deal amortization 28,958 30,184 28,056 Impairment of assets 97,230 — — Contingent consideration (income) expense (4,727 ) (2,918 ) 45 Operating (loss) income $ (43,942 ) $ 40,540 $ 46,432 (In thousands) April 2, March 28, March 29, Depreciation and amortization Japan $ 774 $ 767 $ 839 EMEA 5,146 5,045 4,695 North America Plasma 12,944 11,229 8,776 All Other 71,047 69,012 67,430 Total depreciation and amortization (excluding impairment charges) $ 89,911 $ 86,053 $ 81,740 (In thousands) April 2, March 28, March 29, Long-lived assets (1) Japan $ 33,159 $ 31,810 $ 28,544 EMEA 63,861 66,223 59,034 North America Plasma 116,001 101,272 75,597 All Other 124,613 122,643 108,262 Total long-lived assets $ 337,634 $ 321,948 $ 271,437 (1) Long-lived assets are comprised of property, plant and equipment. Long-lived assets in our principle operating regions are as follows: April 2, March 28, March 29, United States $ 231,744 $ 208,439 $ 185,227 Japan 2,022 1,618 2,563 Europe 18,672 27,786 37,154 Asia 40,235 39,032 8,785 Other 44,961 45,073 37,708 Total $ 337,634 $ 321,948 $ 271,437 Net revenues by product line are as follows: (In thousands) April 2, March 28, March 29, Disposable revenues Plasma disposables $ 348,785 $ 319,190 $ 291,895 Blood center disposables Platelet 143,274 152,588 156,643 Red cell 39,256 42,700 42,378 Whole blood 128,532 143,905 190,698 311,062 339,193 389,719 Hospital disposables Diagnostics 50,882 42,187 33,302 Surgical 59,902 62,540 66,876 OrthoPAT 13,823 20,316 25,042 124,607 125,043 125,220 Disposables revenue 784,454 783,426 806,834 Software solutions 72,434 72,185 70,441 Equipment & other 51,944 54,762 61,234 Net revenues $ 908,832 $ 910,373 $ 938,509 Net revenues generated in our principle operating regions are as follows: April 2, March 28, March 29, United States $ 519,440 $ 494,788 $ 500,719 Japan 81,411 88,298 108,679 Europe 187,725 215,575 224,792 Asia 111,758 102,095 94,762 Other 8,498 9,617 9,557 Total $ 908,832 $ 910,373 $ 938,509

RESTRUCTURING

RESTRUCTURING	12 Months Ended
	Apr. 02, 2016
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business. During the first quarter of fiscal 2017, in connection with our global strategic review, we launched the first phase of a restructuring program designed to reposition our organization and improve our cost structure. The first phase includes both a reduction of headcount and operating costs as well as projects to simplify product lines. We may also take additional steps to modify our manufacturing operations to reflect our strategic direction. We expect to incur approximately $26 million of restructuring and transformation charges, comprised of $17 million in termination benefits and $9 million in other related exit costs. Substantially all of these charges will result in future cash outlays and are expected to be incurred during fiscal 2017. Savings from this program are estimated to be approximately $40 million in fiscal 2017. Subsequent phases of the program may require restructuring charges in future fiscal years. In fiscal 2016, we completed our Value Creation and Capture (“VCC”) opportunities initiative. This initiative included (i) discontinuation of manufacturing activities at our Ascoli-Piceno, Italy and Braintree, Massachusetts facilities, (ii) expansion of our current facility in Tijuana, Mexico, (iii) transfer of all equipment production to our contract manufacturer, Sanmina Corporation, and (iv) consolidation of the manufacturing of product formerly produced in the U.S. and Italy to our new manufacturing facility in Penang, Malaysia. We continue to manufacture in Bothwell, Scotland. The cumulative restructuring charges incurred as a result of the VCC initiative were $100.1 million . The following summarizes the restructuring activity for the fiscal year ended April 2, 2016 , March 28, 2015 , and March 29, 2014 , respectively: (In thousands) Severance and Other Employee Costs Other Costs Accelerated Depreciation Asset Total Restructuring Balance at March 30, 2013 $ 3,089 $ 173 $ — $ — $ 3,262 Costs incurred 31,492 14,254 2,390 915 49,051 Payments (11,673 ) (13,699 ) — — (25,372 ) Non-cash adjustments — — (2,390 ) (915 ) (3,305 ) Balance at March 29, 2014 $ 22,908 $ 728 $ — $ — $ 23,636 Costs incurred 19,879 15,362 1,326 296 36,863 Payments (26,394 ) (15,871 ) — — (42,265 ) Non-cash adjustments — — (1,326 ) (296 ) (1,622 ) Balance at March 28, 2015 $ 16,393 $ 219 $ — $ — $ 16,612 Costs incurred 10,707 7,846 1,469 3,033 23,055 Payments (18,348 ) (8,065 ) — — (26,413 ) Non-cash adjustments — — (1,469 ) (3,033 ) (4,502 ) Balance at April 2, 2016 $ 8,752 $ — $ — $ — $ 8,752 The substantial majority of restructuring expenses have been included as a component of selling, general and administrative expense in the accompanying consolidated statements of (loss) income. Total restructuring charges for fiscal 2016 include a $3.0 million asset write down to fair value related to land, buildings and related equipment for a property we plan to dispose of, as discussed in Note 12, Property Plant and Equipment . As of April 2, 2016, we had a restructuring liability of $8.8 million , of which, approximately $8.1 million is payable within the next twelve months. In addition to the restructuring expenses included in the table above, we also incurred $19.2 million of costs that do not constitute as restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, product line transfer teams and related costs, infrastructure related costs, accelerated depreciation and asset disposals. These costs exclude the impact of contingent consideration of $4.9 million which was reversed during the third quarter of fiscal 2016 and is presented within the contingent consideration (income) expense line on the consolidated statements of (loss) income. The contingent consideration reversal of $2.9 million and an insignificant amount were also excluded for fiscal 2015 and fiscal 2014 , respectively. The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and other expense, net in our consolidated statements of (loss) income for the periods presented. Transformation costs (in thousands) 2016 2015 2014 Transformation and other costs $ 17,377 $ 26,979 $ 30,656 Accelerated depreciation 155 930 4,203 Asset disposal 1,697 4,925 796 Total $ 19,229 $ 32,834 $ 35,655 The tables below present restructuring and transformation costs by reportable segment: Restructuring costs (in thousands) 2016 2015 2014 Japan $ 9 $ 258 $ 372 EMEA 3,210 3,310 1,444 North America Plasma — 360 42 All Other 19,836 32,935 47,193 Total $ 23,055 $ 36,863 $ 49,051 Transformation costs (in thousands) 2016 2015 2014 Japan $ 416 $ 158 $ 131 EMEA 961 838 1,260 North America Plasma — 28 — All Other 17,852 31,810 34,264 Total $ 19,229 $ 32,834 $ 35,655 Total restructuring and transformation $ 42,284 $ 69,697 $ 84,706

CAPITALIZATION OF SOFTWARE DEVE

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
	Apr. 02, 2016
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other . Pursuant to ASC Topic 350, we capitalize costs incurred during the application development stage of software developed for internal use, and expense costs incurred during the preliminary project and the post-implementation operation stages of development. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. For costs incurred related to the development of software to be sold, leased, or otherwise marketed, we apply the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed , which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $17.0 million and $9.5 million in software development costs for ongoing initiatives during the fiscal years ended April 2, 2016 and March 28, 2015 , respectively. At April 2, 2016 and March 28, 2015 , we have a total of $54.9 million and $39.7 million of software costs capitalized, of which $14.4 million and $7.9 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. In connection with these development activities, we capitalized interest of $0.2 million and $0.2 million in fiscal 2016 and 2015 , respectively. We amortize capitalized costs when the products are released for sale. During fiscal 2016 , $8.7 million of capitalized costs were placed into service, compared to $15.7 million of capitalized costs placed into service during fiscal 2015 . Amortization of capitalized software development cost expense was $10.9 million , $3.2 million and $1.1 million for fiscal 2016 , 2015 and 2014 , respectively. Amortization expense in fiscal 2016 includes $6.0 million of impairment charges related to the discontinuance of certain capitalized software projects as a result of our global strategic review in the fourth quarter of fiscal 2016 . These impairment charges are classified within costs of goods sold on our consolidated statements of (loss) income and relate to capitalized software projects included in our All Other segment.

SUMMARY OF QUARTERLY DATA (UNAU

SUMMARY OF QUARTERLY DATA (UNAUDITED)	12 Months Ended
	Apr. 02, 2016
Quarterly Financial Data [Abstract]
SUMMARY OF QUARTERLY DATA (UNAUDITED)	SUMMARY OF QUARTERLY DATA (UNAUDITED) (In thousands) Three months ended Fiscal 2016 June 27, September 26, December 26, April 2, Net revenues $ 213,413 $ 219,693 $ 233,384 $ 242,342 Gross profit $ 102,539 $ 105,297 $ 108,855 $ 89,223 Operating income (loss) $ 3,606 $ 19,179 $ (61,177 ) $ (5,550 ) Net (loss) income $ (267 ) $ 12,863 $ (59,440 ) $ (8,735 ) Per share data: Net (loss) income: Basic $ (0.01 ) $ 0.25 $ (1.17 ) $ (0.17 ) Diluted $ (0.01 ) $ 0.25 $ (1.17 ) $ (0.17 ) (In thousands) Three months ended Fiscal 2015 June 28, September 27, December 27, March 28, Net revenues $ 224,488 $ 227,580 $ 231,827 $ 226,478 Gross profit $ 106,278 $ 108,114 $ 111,661 $ 108,365 Operating (loss) income $ (1,666 ) $ 12,407 $ 18,260 $ 11,539 Net (loss) income $ (3,649 ) $ 7,487 $ 15,988 $ (2,929 ) Per share data: Net (loss) income: Basic $ (0.07 ) $ 0.15 $ 0.31 $ (0.06 ) Diluted $ (0.07 ) $ 0.14 $ 0.31 $ (0.06 ) The operating results for the first quarter of fiscal 2016 include the correction of an understatement of the provision for income taxes in fiscal 2015 as well as other certain out of period items, which were determined to be immaterial to all periods presented. Absent this correction, our operating income and net income for the three months ended June 27, 2015 would have been $0.8 million lower and $0.2 million higher, respectively, than the amount included above. The operating results for the third quarter of fiscal 2016 include the correction of an overstated liability in fiscal 2014 and certain other out of period items, which were determined to be immaterial to all periods presented. Absent these corrections, our operating loss and net loss for the three months ended December 26, 2015 would have been $4.1 million higher and $4.0 million higher, respectively, than the amount included above. The operating results for the fourth quarter of fiscal 2016 include corrections of certain out of period items, the impact of which were determined to be immaterial to all periods presented. Absent these corrections, our operating loss and net loss for the three months ended April 2, 2016 would have been $2.9 million lower and $1.8 million lower, respectively, than the amount included above.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	12 Months Ended
	Apr. 02, 2016
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended April 2, 2016 and March 28, 2015 : (In thousands) Foreign currency Defined benefit plans Net Unrealized Gain/loss on Derivatives Total Balance as of March 29, 2014 $ 3,198 $ (4,592 ) $ 2,804 $ 1,410 Other comprehensive (loss) income before reclassifications (23,710 ) (4,410 ) 11,371 (16,749 ) Amounts reclassified from accumulated other comprehensive loss — 79 (6,464 ) (6,385 ) Net current period other comprehensive (loss) income (23,710 ) (4,331 ) 4,907 (23,134 ) Balance as of March 28, 2015 $ (20,512 ) $ (8,923 ) $ 7,711 $ (21,724 ) Other comprehensive (loss) income before reclassifications (1,987 ) 884 (3,938 ) (5,041 ) Amounts reclassified from accumulated other comprehensive loss — 547 (8,822 ) (8,275 ) Net current period other comprehensive (loss) income (1,987 ) 1,431 (12,760 ) (13,316 ) Balance as of April 2, 2016 $ (22,499 ) $ (7,492 ) $ (5,049 ) $ (35,040 ) The details about the amount reclassified from accumulated other comprehensive loss for the years ended April 2, 2016 and March 28, 2015 are as follows: (In thousands) Amounts Reclassified from Accumulated Other Comprehensive Loss Affected Line in the Statement of (Loss) Income Derivative instruments reclassified to income statement Year ended April 2, 2016 Year ended March 28, 2015 Realized net gain on derivatives $ 8,654 $ 6,736 Net revenues, cost of goods sold, other expense, net Income tax effect 168 (272 ) Provision for income taxes Net of taxes $ 8,822 $ 6,464 Pension items reclassified to income statement Realized net loss on pension assets $ 602 $ 123 Other expense, net Income tax effect (55 ) (44 ) Provision for income taxes Net of taxes $ 547 $ 79

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Apr. 02, 2016
Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II HAEMONETICS CORPORATION VALUATION AND QUALIFYING ACCOUNTS (In thousands) Balance at Charged to Write-Offs Balance at End For Year Ended April 2, 2016 Allowance for Doubtful Accounts $ 1,749 $ 728 $ (224 ) $ 2,253 For Year Ended March 28, 2015 Allowance for Doubtful Accounts $ 1,676 $ 399 $ (326 ) $ 1,749 For Year Ended March 29, 2014 Allowance for Doubtful Accounts $ 1,727 $ 186 $ (237 ) $ 1,676

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Apr. 02, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Fiscal Year	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal year 2016 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks. Fiscal year 2015 and 2014 included 52 weeks with each quarter having 13 weeks.
Principles of Consolidation	The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions. We consider estimates to be critical if we are required to make assumptions about material matters that are uncertain at the time of estimation or if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: revenue recognition, allowance for doubtful accounts, inventory provisions, intangible asset and goodwill valuation, legal and other judgmental accruals, and income taxes.
Reclassifications	Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.
Contingencies	We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, employee related litigation, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a loss is probable and a range of loss is established but a best estimate cannot be made, we record the minimum loss contingency amount, which could be zero. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. As information becomes known, an additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount.
Revenue Recognition	Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition , and ASC Topic 985-605, Software . These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software , we establish fair value of undelivered elements based upon vendor specific objective evidence. We offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum potential rebate or discount that could be earned. In circumstances where we provide upfront rebate payments to customers, we capitalize the rebate payments and amortize the resulting asset as a reduction of revenue using a systematic method over the life of the contract.
Product Revenues	Product sales consist of the sale of our disposable blood component collection and processing sets and the related equipment. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product. We also place equipment at customer sites. While we retain ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. We recover the cost of providing the equipment from the sale of disposables.
Software Revenues	Our software solutions business provides support to our plasma, blood collection and hospital customers. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. For hospitals, we provide solutions to help improve patient safety, reduce cost and ensure compliance. Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees. We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.
Non-Income Taxes	We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority. We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses. In December 2015, this tax was suspended for two years, beginning on January 1, 2016. This tax may be imposed again beginning on January 1, 2018, unless the suspension is extended or the medical device excise tax is permanently repealed.
Translation of Foreign Currencies	All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of (loss) income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss on the consolidated balance sheet.
Cash and Cash Equivalents	Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of April 2, 2016 , our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds.
Allowance for Doubtful Accounts	We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience.
Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. We have based our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. Significant changes in the timing or level of demand for our products results in recording additional provisions for excess, expired and obsolete inventory. Additionally, uncertain timing of next-generation product approvals, variability in product launch strategies, non-cancelable purchase commitments, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
Property, Plant and Equipment	Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows: Asset Classification Estimated Useful Lives Building 30 Years Building improvements 5-20 Years Plant equipment and machinery 3-15 Years Office equipment and information technology 2-10 Years Haemonetics equipment 3-7 Years We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following: • Purchase and consumption of a certain level of disposable products • Payment of monthly rental fees • An asset utilization performance metric, such as performing a minimum level of procedures per month per device Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for disposables used with these devices, from which we generate revenues. We also consider product life cycle in our evaluation of useful life and recoverability. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results. Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income.
Goodwill and Other Intangible Assets	Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("Topic 350"), or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. In performing our goodwill impairment assessment, we utilize the two-step approach prescribed under Topic 350. The first step requires a comparison of the carrying value of the reporting units, as defined, to the fair value of these units. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We determine our reporting units by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. We aggregate components within an operating segment that have similar economic characteristics. Our reporting units for purposes of assessing goodwill impairment are the same as our operating segments, which are organized primarily based on geography and include: (a) North America Plasma, (b) Americas Blood Center and Hospital, (c) Europe, Middle East, and Africa (collectively "EMEA"), (d) Asia-Pacific and (e) Japan. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the plasma business. When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit. In fiscal 2016 , we used the income approach, specifically the discounted cash flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. We selected this method as being the most meaningful in preparing our goodwill assessments because the use of the income approach typically generates a more precise measurement of fair value than the market approach. Due to the increased adverse business conditions impacting multiple Haemonetics reporting units in fiscal 2016, we determined that a more precise measure of fair value was required when performing our goodwill impairment review compared to what was performed in prior years. In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our discounted cash flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our discounted cash flow analysis and reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk adjusted weighted average cost of capital ("WACC") as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test. In fiscal 2015 and 2014 , we determined the fair value of our reporting units based on the market approach. We utilized the market approach as we determined relevant comparable information was available, and accordingly such method was an appropriate alternative to the income method. Under the market approach, we estimated the fair value of our reporting units based on a combination of, a) market multiples of projected earnings before interest, taxes, depreciation and amortization (“EBITDA”) and b) market multiples of projected net revenues for each individual reporting unit. For the market approach, we used judgment in identifying the relevant comparable-company market multiples, such as recent divestitures/acquisitions, facts and circumstances surrounding the market and growth rates. Management assessed the relevance and reliability of the multiples by considering factors unique to its reporting units, including recent operating results, business plans, economic projections, anticipated future cash flows, and other data. EBITDA and revenue multiples were also significantly impacted by future growth opportunities for the reporting unit as well as for the company itself, general market and geographic sentiment, and pending or recently completed merger transactions. If the carrying value of a reporting unit exceeds its fair value, we perform the second step of the goodwill impairment test to measure the amount of impairment, if any. The second step compares the implied fair value of a reporting unit’s goodwill with its carrying value. To determine the implied fair value of goodwill, we allocate the fair value of a reporting unit to all of the assets and liabilities of that unit, including intangible assets, as if the reporting unit had been acquired in a business combination. Any excess of the value of a reporting unit over the amounts assigned to its assets and liabilities represents the implied fair value of goodwill. In the third quarter of fiscal 2016, we concluded that indicators of potential goodwill impairment were present for the EMEA and Americas Blood Center and Hospital reporting units, requiring an interim test. We recorded a preliminary impairment charge of $66.3 million in the EMEA reporting unit during the third quarter of fiscal 2016. During the fourth quarter of fiscal 2016, we completed our second step of the goodwill impairment test and concluded that no adjustment to the estimated $66.3 million impairment loss initially recorded was required, as there was significant intangible value attributed to customer relationships and developed technology based on the theoretical purchase price allocation. Refer to Note 5, Goodwill and Intangible Assets, for additional details regarding goodwill impairment. We review intangible assets subject to amortization for impairment at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. During fiscal 2016 , 2015 and 2014 , we determined that there were potential impairment indicators for certain intangible assets subject to amortization. As such, we performed the recoverability test described below for the relevant asset groups. In fiscal 2015 and 2014, we determined that the expected undiscounted cash flows exceeded the carrying value of the asset groups identified. In fiscal 2016, however, we determined that the undiscounted cash flows did not support the carrying value of the asset groups identified and, accordingly, recorded impairment charges of $25.8 million , of which $18.7 million related to the write down of the SOLX intangible assets and the remaining $7.1 million related to intangible assets that were identified as part of the Company's global strategic review. Refer to Note 5, Goodwill and Intangible Assets, for additional details regarding intangible asset impairments recorded. When an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified. We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group). If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.
Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed	ASC Topic 985-20, Software , specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of five to 10 years . Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. We capitalize costs associated with both software that we sell as a separate product and software that is embedded in a device. We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. During the fourth quarter of fiscal 2016 , we recorded $6.0 million of impairment charges related to the discontinuance of certain capitalized software projects as a result of our global strategic review. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.
Research and Development Expenses	All research and development costs are expensed as incurred.
Advertising Costs	All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of (loss) income.
Accounting for Shipping and Handling Costs	Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.
Income Taxes	The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable. We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made when necessary. Tax reserves are reversed when the statute of limitations expires or the matter is considered effectively settled. We evaluate at the end of each reporting period whether some or all of the undistributed earnings of our foreign subsidiaries are permanently reinvested. We recognize deferred income tax liabilities to the extent that management asserts that undistributed earnings of its foreign subsidiaries are not permanently reinvested or will not be permanently reinvested in the future. Our position is based upon several factors including management’s evaluation of the Company and its subsidiaries’ financial requirements, the short term and long-term operational and fiscal objectives of the Company, and the tax consequences associated with the repatriation of earnings.
Derivative Instruments	We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes. When the underlying hedged transaction affects earnings, the gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other expense, net in our consolidated statements of (loss) income, depending on the nature of the underlying hedged transactions. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses of $1.4 million , $1.1 million , and $0.5 million in fiscal 2016 , 2015 and 2014 , respectively. On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.
Stock-Based Compensation	We expense the fair value of stock-based awards granted to employees, board members and others, net of estimated forfeitures. To calculate the grant-date fair value of our stock options we use the Black-Scholes option-pricing model and for performance share units and market stock units we use Monte Carlo simulation models.
Valuation of Acquisitions	We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, we periodically revalue the contingent consideration obligations associated with certain acquisitions to their current fair value and record the change in the fair value as contingent consideration income or expense within selling, general and administrative expense. These changes are recorded in selling, general and administrative expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.
Concentration of Credit Risk and Significant Customers	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2016 , 2015 , and 2014 no customer accounted for more than 10% of our revenues. Certain other markets and industries can expose us to concentrations of credit risk. For example, in our plasma business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these bio-pharmaceutical customers can be significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.
Recent Accounting Pronouncements	Standards Implemented In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity . ASU No. 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in ASU No. 2014-08 are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. We adopted ASU No. 2014-08 beginning in the first quarter of fiscal 2016. The adoption of ASU No. 2014-08 did not impact our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance simplifies the presentation of debt issuance costs but does not address presentation or subsequent measurement of debt issue costs related to line of credit arrangements. In August 2015, the FASB issued ASU No. 2015-15, Interest—Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements. ASU No. 2015-15 indicates that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to line of credit arrangements as an asset and subsequently amortizing the deferred debt issuance costs over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. ASU No. 2015-03 is effective for annual periods beginning after December 15, 2015, and interim periods within those annual periods. Early adoption is permitted. We early adopted ASU No. 2015-03 in the fourth quarter of fiscal 2016. Our debt issuance costs related to a recognized debt liability are presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The adoption of ASU No. 2015-03 did not have a material impact our financial position or results of operations. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes . ASU No. 2015-17 simplifies the presentation of deferred taxes on a classified balance sheet. Currently under U.S. GAAP, deferred income tax assets and liabilities are separated into current and non-current amounts in the balance sheet. ASU No. 2015-17 requires that all deferred tax assets and liabilities be classified as non-current in the balance sheet. ASU No. 2015-17 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, with early adoption permitted. We early adopted ASU No. 2015-17 in the fourth quarter of fiscal 2016. ASU No. 2015-17 was adopted retrospectively and, as a result, the consolidated balance sheet as of March 28, 2015 was adjusted. The March 28, 2015 current deferred tax assets and liabilities of $12.6 million and $0.4 million , respectively, were reclassified as long-term. The adoption of ASU No. 2015-17 had an impact on the presentation of our consolidated balance sheet, but did not impact our financial position or results of operations. Standards to be Implemented In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. Early adoption is permitted for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The impact of adopting ASU No. 2014-09 on our financial position and results of operations is being assessed by management. In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period . ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. ASU No. 2014-12 is effective in our first quarter of fiscal 2017 with early adoption permitted using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU No. 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. Management does not believe that the adoption of ASU No. 2014-12 will have a material effect on our financial position or results of operations. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. Management does not believe that the adoption of ASU No. 2014-15 will have a material effect on our financial position or results of operations. In August 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), Health and Welfare Benefit Plans (Topic 965): (Part I) Fully Benefit-Responsive Investment Contracts, (Part II) Plan Investment Disclosures, (Part III) Measurement Date Practical Expedient . Part I of ASU No. 2015-12 designates contract value as the only required measure for fully benefit-responsive investment contracts. Part II simplifies the investment disclosure requirements under Topics 820, 960, 962, and 965 for employee benefits plans and Part III provides a measurement date practical expedient for fiscal periods that do not coincide with a month-end date. ASU No. 2015-12 is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. Management does not believe that the adoption of ASU No. 2015-12 will have a material effect on our financial position or results of operations. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . ASU No. 2016-01 requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with changes recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. It also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. ASU No. 2016-01 also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset and liability. ASU No. 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of certain provisions is permitted. Management does not believe that the adoption of ASU No. 2016-01 will have a material effect on our financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . ASU No. 2016-02 is intended to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP, and disclosing key information about leasing arrangements. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier adoption is permitted. The impact of adopting ASU No. 2016-02 on our financial position and results of operations is being assessed by management. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . The purpose of ASU No. 2016-08 is to clarify the guidance on principal versus agent considerations. It includes indicators that help to determine whether an entity controls the specified good or service before it is transferred to the customer and to assist in determining when the entity satisfied the performance obligation and as such, whether to recognize a gross or a net amount of consideration in their consolidated statement of operations. The effective date and transition requirements are consistent with ASU No. 2014-09. The impact of adopting ASU No. 2016-08 on our financial position and results of operations is being assessed by management. In March 2016, the FASB issued ASU No. 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The purpose of the update is to simplify several areas of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU No. 2016-09 is effective for annual reporting periods after December 15, 2016, including interim periods within those fiscal periods. Early adoption is permitted. The impact of adopting ASU No. 2016-09 on our financial position and results of operations is being assessed by management. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing . The guidance clarifies that entities are not required to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract. ASU No. 2016-10 also addresses how to determine whether promised goods or services are separately identifiable and permits entities to make a policy election to treat shipping and handling costs as fulfillment activities. In addition, it clarifies key provisions in Topic 606 related to licensing. The effective date and transition requirements are consistent with ASU No. 2014-09. The impact of adopting ASU No. 2016-10 on our financial position and results of operations is being assessed by management.

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Apr. 02, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Schedule of Property, Plant and Equipment Estimated Useful Lives	Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows: Asset Classification Estimated Useful Lives Building 30 Years Building improvements 5-20 Years Plant equipment and machinery 3-15 Years Office equipment and information technology 2-10 Years Haemonetics equipment 3-7 Years
Schedule of Other Accrued Liabilities	Other Current Liabilities Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were: (In thousands) April 2, March 28, VAT liabilities $ 1,289 $ 4,205 Forward contracts 4,210 2,657 Deferred revenue 27,053 22,362 Accrued taxes 3,876 3,819 All other 30,180 34,579 Total $ 66,608 $ 67,622 Other Long-Term Liabilities Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were: (In thousands) April 2, March 28, Unfunded pension liability 18,067 17,402 Unrecognized tax benefit 2,283 3,992 All other 5,756 10,343 Total $ 26,106 $ 31,737

PRODUCT WARRANTIES (Tables)

PRODUCT WARRANTIES (Tables)	12 Months Ended
	Apr. 02, 2016
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary. (In thousands) April 2, March 28, Warranty accrual as of the beginning of the year $ 531 $ 590 Warranty provision 948 1,199 Warranty spending (1,059 ) (1,258 ) Warranty accrual as of the end of the year $ 420 $ 531

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Apr. 02, 2016
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. (In thousands) April 2, March 28, Raw materials $ 62,062 $ 71,794 Work-in-process 13,180 12,462 Finished goods 111,786 126,821 Total Inventories $ 187,028 $ 211,077

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Apr. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by reporting segment for fiscal 2016 and 2015 are as follows: (In thousands) Japan EMEA North America Plasma All Other Total Carrying amount as of March 29, 2014 $ 25,477 $ 74,019 $ 26,415 $ 210,857 $ 336,768 Currency translation (578 ) (1,324 ) — (556 ) (2,458 ) Carrying amount as of March 28, 2015 $ 24,899 $ 72,695 $ 26,415 $ 210,301 $ 334,310 Impairment charge — (66,305 ) — — (66,305 ) Transfer of goodwill between segments — (6,390 ) — 6,390 — Currency translation (16 ) — — (149 ) (165 ) Carrying amount as of April 2, 2016 $ 24,883 $ — $ 26,415 $ 216,542 $ 267,840
Schedule of Amoritized Intangibles	The gross carrying amount of intangible assets and the related accumulated amortization as of April 2, 2016 and March 28, 2015 is as follows: (In thousands) Gross Carrying Amount Accumulated Amortization (1) Net Weighted Average Useful Life (In years) As of April 2, 2016 Amortizable: Patents $ 8,545 $ 7,542 $ 1,003 9 Capitalized software 40,488 14,791 25,697 6 Other developed technology 126,142 73,475 52,667 12 Customer contracts and related relationships 196,085 89,804 106,281 10 Trade names 7,083 5,204 1,879 11 Total $ 378,343 $ 190,816 $ 187,527 10 Non-amortizable: In-process software development $ 14,427 In-process patents 2,504 Total $ 16,931 (1) Includes impairment of SOLX and other intangible assets, as discussed below. (In thousands) Gross Carrying Amount Accumulated Amortization Net Weighted Average Useful Life (In years) As of March 28, 2015 Amortizable: Patents $ 7,686 $ 7,373 $ 313 9 Capitalized software 31,818 5,654 26,164 7 Other developed technology 124,573 46,474 78,099 12 Customer contracts and related relationships 195,985 70,440 125,545 10 Trade names 7,042 3,234 3,808 11 Total $ 367,104 $ 133,175 $ 233,929 10 Non-amortizable: In-process software development $ 7,872 In-process patents 2,787 Total $ 10,659
Schedule of Future Amortization Expense	Future annual amortization expense on intangible assets is estimated to be as follows: Fiscal Year Amount (in thousands) 2017 $ 31,397 2018 $ 30,959 2019 $ 29,250 2020 $ 27,353 2021 $ 25,512

DERIVATIVES AND FAIR VALUE ME32

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Apr. 02, 2016
Derivatives and Fair Value Measurements [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of (loss) income and comprehensive (loss) income for the fiscal year ended April 2, 2016 . Derivative Instruments Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive (Loss) Income Amount of Gain Reclassified from Accumulated Other Comprehensive (Loss) Income into Earnings Location in Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income Amount of Gain (Loss) Excluded from Testing (*) Location in Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (In thousands) Designated foreign currency hedge contracts, net of tax $ (3,940 ) $ 8,822 Net revenues, COGS, and SG&A $ 102 Other expense, net Non-designated foreign currency hedge contracts — — $ (203 ) Other expense, net Designated interest rate swaps, net of tax $ 2 $ — Other expense, net $ — (*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets: (In thousands) Location in Balance Sheet Balance as of April 2, 2016 Balance as of March 28, 2015 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 427 $ 9,740 Designated interest rate swaps Other current assets — — $ 427 $ 9,740 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 4,056 $ 2,499 Designated interest rate swaps Other current liabilities 154 159 $ 4,210 $ 2,658
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following: As of April 2, 2016 Level 1 Level 2 Level 3 Total (In thousands) Assets Money market funds $ 72,491 $ — $ — $ 72,491 Designated foreign currency hedge contracts — 427 — 427 $ 72,491 $ 427 $ — $ 72,918 Liabilities Designated foreign currency hedge contracts $ — $ 4,056 $ — $ 4,056 Designated interest rate swaps — 154 — 154 Contingent consideration — — — — $ — $ 4,210 $ — $ 4,210 As of March 28, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets Money market funds $ 119,946 $ — $ — $ 119,946 Designated foreign currency hedge contracts — 9,740 — 9,740 $ 119,946 $ 9,740 $ — $ 129,686 Liabilities Forward currency hedge contracts $ — $ 2,499 $ — $ 2,499 Designated interest rate swaps — 159 — 159 Contingent consideration — — 4,727 4,727 $ — $ 2,658 $ 4,727 $ 7,385
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the year ended April 2, 2016 . (In thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance at March 28, 2015 $ 4,727 Fair value adjustment (4,727 ) Balance at April 2, 2016 $ —

NOTES PAYABLE AND LONG-TERM D33

NOTES PAYABLE AND LONG-TERM DEBT (Tables)	12 Months Ended
	Apr. 02, 2016
Debt Disclosure [Abstract]
Schedule of Notes Payable and Long-Term Debt	Notes payable and long-term debt consisted of the following: (In thousands) April 2, 2016 March 28, 2015 Term loan, net of financing fees $ 406,175 $ 426,814 Real estate mortgage — 851 Bank loans and other borrowings 1,825 226 Less current portion (43,471 ) (21,522 ) Long-term debt $ 364,529 $ 406,369
Schedule of Notes Payable and Long-Term Debt Maturities	The maturity profile of all gross long-term debt, exclusive of debt discounts, as of April 2, 2016 is presented below: Fiscal year (in thousands) Credit Facilities Bank loans and other borrowings Total 2017 $ 42,683 $ 154 $ 42,837 2018 45,054 108 45,162 2019 151,763 89 151,852 2020 168,564 50 168,614 $ 408,064 $ 401 $ 408,465

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Apr. 02, 2016
Income Tax Disclosure [Abstract]
Schedule Domestic and Foreign Income Before Provision for Income Tax	Domestic and foreign income before provision for income tax is as follows: (In thousands) April 2, March 28, March 29, Domestic $ (18,526 ) $ (17,265 ) $ (6,859 ) Foreign (34,890 ) 48,430 43,260 Total $ (53,416 ) $ 31,165 $ 36,401
Schedule of Income Tax Provision Components	The income tax provision from continuing operations contains the following components: (In thousands) April 2, March 28, March 29, Current Federal $ 12 $ 3,526 $ (4,896 ) State (660 ) 898 873 Foreign 3,842 5,614 5,478 Total current $ 3,194 $ 10,038 $ 1,455 Deferred Federal 3,532 1,227 (1,785 ) State 319 3,215 207 Foreign (4,882 ) (212 ) 1,376 Total deferred $ (1,031 ) $ 4,230 $ (202 ) Total $ 2,163 $ 14,268 $ 1,253
Schedule of Net Deferred Tax Asset	Tax affected, significant temporary differences comprising the net deferred tax liability are as follows: (In thousands) April 2, March 28, Deferred tax assets: Depreciation $ 1,749 $ 609 Amortization of intangibles 4,417 727 Inventory 7,607 6,193 Hedging 382 84 Accruals, reserves and other deferred tax assets 12,590 17,526 Net operating loss carry-forward 13,484 5,392 Stock based compensation 9,622 10,652 Tax credit carry-forward, net 16,191 8,678 Gross deferred tax assets 66,042 49,861 Less valuation allowance (24,297 ) (16,027 ) Total deferred tax assets (after valuation allowance) 41,745 33,834 Deferred tax liabilities: Depreciation (28,972 ) (24,342 ) Amortization of goodwill and intangibles (23,626 ) (24,764 ) Unremitted earnings (700 ) — Other deferred tax liabilities (2,769 ) (1,604 ) Total deferred tax liabilities (56,067 ) (50,710 ) Net deferred tax liabilities $ (14,322 ) $ (16,876 )
Schedule of Effective Income Tax Rate Reconciliation	The income tax provision from continuing operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following: (In thousands) April 2, March 28, March 29, Tax at federal statutory rate $ (18,695 ) 35.0 % $ 10,907 35.0 % $ 12,739 35.0 % Difference between U.S. and foreign tax 10,645 (19.9 )% (6,929 ) (22.2 )% (10,846 ) (29.8 )% State income taxes net of federal benefit 134 (0.3 )% (818 ) (2.6 )% (252 ) (0.7 )% Change in uncertain tax positions (1,820 ) 3.4 % (1,762 ) (5.7 )% (1,678 ) (4.6 )% Intercompany loan deduction — — % — — % (2,185 ) (6.0 )% Unremitted earnings 735 (1.4 )% — — % — — % Deferred statutory rate changes (2,653 ) 5.0 % — — % — — % Non-deductible goodwill impairment 2,861 (5.4 )% — — % — — % Non-deductible expenses 1,491 (2.8 )% 1,237 4.0 % 1,035 2.8 % Research credits (672 ) 1.3 % (1,000 ) (3.2 )% (688 ) (1.9 )% Tax amortization of goodwill 4,185 (7.8 )% 3,826 12.3 % — — % Valuation allowance 5,194 (9.7 )% 8,524 27.4 % 2,400 6.6 % Other, net 758 (1.4 )% 283 0.8 % 728 2.0 % Income tax provision $ 2,163 (4.0 )% $ 14,268 45.8 % $ 1,253 3.4 %
Summary of Gross Unrecognized Tax Benefits	The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended April 2, 2016 , March 28, 2015 and March 29, 2014 : (In thousands) April 2, March 28, March 29, Beginning Balance $ 7,070 $ 5,604 $ 6,930 Additions based upon positions related to the current year — — — Additions for tax positions of prior years 340 3,234 990 Reductions of tax positions (4,158 ) — — Settlements with taxing authorities — (338 ) — Closure of statute of limitations (729 ) (1,430 ) (2,316 ) Ending Balance $ 2,523 $ 7,070 $ 5,604

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Apr. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Approximate Future Basic Rental Commitments under Operating Leases	Approximate future basic rental commitments under operating leases as of April 2, 2016 are as follows: Fiscal Year Ending (In thousands) 2017 $ 4,845 2018 3,830 2019 2,476 2020 1,820 2021 1,708 Thereafter 6,143 $ 20,822

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	12 Months Ended
	Apr. 02, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Cost	Compensation cost related to stock-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of stock-based compensation expense, which is recorded on a straight line basis, was as follows: (In thousands) 2016 2015 2014 Selling, general and administrative expenses $5,183 $11,251 $10,507 Research and development 1,060 1,706 1,545 Cost of goods sold 706 1,138 1,030 $6,949 $14,095 $13,082
Schedule of Summary of Stock Option Activity	A summary of stock option activity for the fiscal year ended April 2, 2016 is as follows: Options Outstanding (shares) Weighted Average Exercise Price per Share Weighted Average Remaining Life (years) Aggregate Intrinsic Value ($000’s) Outstanding at March 28, 2015 3,761,666 $ 33.90 4.02 $ 37,067 Granted 409,047 32.50 Exercised (491,546 ) 28.55 Forfeited/Canceled (727,984 ) 37.98 Outstanding at April 2, 2016 2,951,183 $ 33.59 3.34 $ 9,684 Exercisable at April 2, 2016 2,288,166 $ 33.22 2.59 $ 8,428 Vested or expected to vest at April 2, 2016 2,847,285 $ 33.56 3.21 $ 9,432
Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants	The assumptions utilized for option grants during the periods presented are as follows: April 2, March 28, March 29, Volatility 22.8 % 22.5 % 24.8 % Expected life (years) 4.9 4.9 4.9 Risk-free interest rate 1.4 % 1.5 % 1.3 % Dividend yield 0.0 % 0.0 % 0.0 % Fair value per option $ 7.40 $ 7.91 $ 10.15
Schedule of Assumptions Used, Other than Options	The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions: April 2, March 28, March 29, Volatility 21.1 % 23.7 % 22.9 % Expected life (months) 6 6 6 Risk-free interest rate 0.2 % 0.1 % 0.1 % Dividend Yield 0.0 % 0.0 % 0.0 % The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows: (In thousands, except per share data) April 2, March 28, March 29, Grant-date fair value per RSU $ 33.19 $ 34.89 $ 42.24 Fair value of RSUs vested $ 36.07 $ 36.62 $ 32.70 The Company uses the Monte Carlo model to determine the fair value of each market stock unit. The assumptions used in the Monte Carlo model for MSUs granted during each year were as follows: April 2, March 28, March 29, Volatility 24.0 % 21.2 % 20.2 % Expected life (years) 1.7 2.8 3.7 Risk-free interest rate 0.5 % 0.8 % 0.9 % Dividend yield 0.0 % 0.0 % 0.0 % The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows: April 2, March 28, Expected stock price volatility 22.27 % 20.08 % Peer group stock price volatility 31.95 % 31.52 % Correlation of returns 26.27 % 30.52 % The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows: April 2, March 28, March 29, Discount rate 0.72 % 0.93 % 2.02 % Rate of increased salary levels 1.58 % 1.65 % 1.57 % Expected long-term rate of return on assets 1.20 % 1.68 % 1.94 %
Schedule of Summary of Restricted Stock Units Activity	The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant. A summary of RSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 357,547 $ 36.73 Granted 278,260 33.19 Vested (112,333 ) 36.07 Forfeited (142,603 ) 36.72 Unvested at April 2, 2016 380,871 $ 34.33
Schedule of Performance Share Unit awards	A summary of PSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 129,130 $ 35.09 Granted 80,145 29.20 Vested — — Forfeited (106,939 ) 34.22 Unvested at April 2, 2016 102,336 $ 31.38
Schedule of Market Stock Units Award Activity	A summary of MSU activity for the fiscal year ended April 2, 2016 is as follows: Shares Weighted Average Grant Date Fair Value Unvested at March 28, 2015 287,682 $ 33.90 Granted 33,550 10.21 Vested — — Forfeited (168,264 ) 37.42 Unvested at April 2, 2016 152,968 $ 24.84

EARNINGS PER SHARE ("EPS") (Tab

EARNINGS PER SHARE ("EPS") (Tables)	12 Months Ended
	Apr. 02, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. (In thousands, except per share amounts) April 2, March 28, March 29, Basic EPS Net (loss) income $ (55,579 ) $ 16,897 $ 35,148 Weighted average shares 50,910 51,533 51,611 Basic (loss) income per share $ (1.09 ) $ 0.33 $ 0.68 Diluted EPS Net (loss) income $ (55,579 ) $ 16,897 $ 35,148 Basic weighted average shares 50,910 51,533 51,611 Net effect of common stock equivalents — 556 766 Diluted weighted average shares 50,910 52,089 52,377 Diluted (loss) income per share $ (1.09 ) $ 0.32 $ 0.67

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Apr. 02, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following: (In thousands) April 2, 2016 March 28, 2015 Land $ 7,905 $ 9,468 Building and building improvements 117,132 118,384 Plant equipment and machinery 238,549 220,793 Office equipment and information technology 127,019 118,810 Haemonetics equipment 295,853 264,307 Total 786,458 731,762 Less: accumulated depreciation and amortization (448,824 ) (409,814 ) Property, plant and equipment, net $ 337,634 $ 321,948

RETIREMENT PLANS (Tables)

RETIREMENT PLANS (Tables)	12 Months Ended
	Apr. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans	Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components: (In thousands) 2016 2015 2014 Service cost $ 3,560 $ 2,979 $ 3,351 Interest cost on benefit obligation 371 686 623 Expected (return)/loss on plan assets (330 ) (449 ) (435 ) Actuarial loss/(gain) 598 107 88 Amortization of unrecognized prior service cost (38 ) (29 ) 182 Amortization of unrecognized transition obligation 42 45 47 Totals $ 4,203 $ 3,339 $ 3,856
Schedule of Activity Under Defined Benefit Plans	The activity under those defined benefit plans are as follows: (In thousands) April 2, March 28, Change in Benefit Obligation: Benefit Obligation, beginning of year $ (40,567 ) $ (32,621 ) Service cost (3,560 ) (2,979 ) Interest cost (371 ) (686 ) Benefits paid 3,780 4,902 Actuarial (loss)/gain 424 (6,883 ) Employee and plan participants contribution (1,839 ) (2,978 ) Plan Amendments 833 114 Foreign currency changes 3,381 564 Benefit obligation, end of year $ (37,919 ) $ (40,567 ) Change in Plan Assets: Fair value of plan assets, beginning of year $ 23,165 $ 19,981 Company contributions 1,987 2,112 Benefits paid (3,779 ) (4,621 ) Gain/(Loss) on plan assets 446 506 Employee and plan participants contributions 1,861 2,851 Foreign currency changes (3,828 ) 2,336 Fair value of Plan Assets, end of year $ 19,852 $ 23,165 Funded Status* $ (18,067 ) $ (17,402 ) Unrecognized net actuarial loss/(gain) 10,168 11,096 Unrecognized initial obligation 37 64 Unrecognized prior service cost (1,186 ) (459 ) Net amount recognized $ (9,048 ) $ (6,701 )
Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax	The components of the change recorded in our accumulated other comprehensive (loss) income related to our defined benefit plans, net of tax, are as follows (in thousands): Balance, March 30, 2013 $ (5,073 ) Obligation at transition 172 Actuarial loss (129 ) Prior service cost 438 Balance as of March 29, 2014 $ (4,592 ) Obligation at transition (19 ) Actuarial loss (6,198 ) Prior service cost 1,886 Balance as of March 28, 2015 $ (8,923 ) Obligation at transition 33 Actuarial loss 681 Prior service cost 717 Balance as of April 2, 2016 $ (7,492 )
Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs	The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions: April 2, March 28, March 29, Volatility 21.1 % 23.7 % 22.9 % Expected life (months) 6 6 6 Risk-free interest rate 0.2 % 0.1 % 0.1 % Dividend Yield 0.0 % 0.0 % 0.0 % The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested were as follows: (In thousands, except per share data) April 2, March 28, March 29, Grant-date fair value per RSU $ 33.19 $ 34.89 $ 42.24 Fair value of RSUs vested $ 36.07 $ 36.62 $ 32.70 The Company uses the Monte Carlo model to determine the fair value of each market stock unit. The assumptions used in the Monte Carlo model for MSUs granted during each year were as follows: April 2, March 28, March 29, Volatility 24.0 % 21.2 % 20.2 % Expected life (years) 1.7 2.8 3.7 Risk-free interest rate 0.5 % 0.8 % 0.9 % Dividend yield 0.0 % 0.0 % 0.0 % The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows: April 2, March 28, Expected stock price volatility 22.27 % 20.08 % Peer group stock price volatility 31.95 % 31.52 % Correlation of returns 26.27 % 30.52 % The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows: April 2, March 28, March 29, Discount rate 0.72 % 0.93 % 2.02 % Rate of increased salary levels 1.58 % 1.65 % 1.57 % Expected long-term rate of return on assets 1.20 % 1.68 % 1.94 %
Schedule of Estimated Future Benefit Payments	Estimated future benefit payments are as follows: (in thousands) Fiscal Year 2017 $ 1,746 Fiscal Year 2018 1,542 Fiscal Year 2019 1,523 Fiscal Year 2020 1,883 Fiscal Year 2021 1,687 Fiscal Year 2022-2026 7,872 $ 16,253

SEGMENT AND ENTERPRISE-WIDE I40

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)	12 Months Ended
	Apr. 02, 2016
Segment Reporting [Abstract]
Selected Information by Business Segment	Selected information by business segment is presented below: (In thousands) April 2, March 28, March 29, Net revenues Japan $ 84,270 $ 83,547 $ 89,041 EMEA 175,874 183,753 193,691 North America Plasma 279,803 240,705 213,215 All Other 370,568 375,827 400,133 Net revenues (constant currency) 910,515 883,832 896,080 Effect of exchange rates (1,683 ) 26,541 42,429 Net revenues (reported) $ 908,832 $ 910,373 $ 938,509 (In thousands) April 2, March 28, March 29, Segment operating income Japan $ 37,165 $ 36,843 $ 38,685 EMEA 36,976 44,998 49,373 North America Plasma 100,367 89,092 82,497 All Other 135,580 142,531 154,099 Segment operating income (constant currency) 310,088 313,464 324,654 Corporate operating expenses (constant currency) (194,361 ) (189,867 ) (186,562 ) Non-GAAP operating income (constant currency) 115,727 123,597 138,092 Effect of exchange rates 3,977 13,906 21,147 Non-GAAP operating income (reported) 119,704 137,503 159,239 Unallocated amounts Restructuring and transformation costs 42,185 69,697 84,706 Deal amortization 28,958 30,184 28,056 Impairment of assets 97,230 — — Contingent consideration (income) expense (4,727 ) (2,918 ) 45 Operating (loss) income $ (43,942 ) $ 40,540 $ 46,432 (In thousands) April 2, March 28, March 29, Depreciation and amortization Japan $ 774 $ 767 $ 839 EMEA 5,146 5,045 4,695 North America Plasma 12,944 11,229 8,776 All Other 71,047 69,012 67,430 Total depreciation and amortization (excluding impairment charges) $ 89,911 $ 86,053 $ 81,740 (In thousands) April 2, March 28, March 29, Long-lived assets (1) Japan $ 33,159 $ 31,810 $ 28,544 EMEA 63,861 66,223 59,034 North America Plasma 116,001 101,272 75,597 All Other 124,613 122,643 108,262 Total long-lived assets $ 337,634 $ 321,948 $ 271,437 (1) Long-lived assets are comprised of property, plant and equipment. Long-lived assets in our principle operating regions are as follows: April 2, March 28, March 29, United States $ 231,744 $ 208,439 $ 185,227 Japan 2,022 1,618 2,563 Europe 18,672 27,786 37,154 Asia 40,235 39,032 8,785 Other 44,961 45,073 37,708 Total $ 337,634 $ 321,948 $ 271,437
Schedule of Revenues by Product Line and Geographic Regions	Net revenues by product line are as follows: (In thousands) April 2, March 28, March 29, Disposable revenues Plasma disposables $ 348,785 $ 319,190 $ 291,895 Blood center disposables Platelet 143,274 152,588 156,643 Red cell 39,256 42,700 42,378 Whole blood 128,532 143,905 190,698 311,062 339,193 389,719 Hospital disposables Diagnostics 50,882 42,187 33,302 Surgical 59,902 62,540 66,876 OrthoPAT 13,823 20,316 25,042 124,607 125,043 125,220 Disposables revenue 784,454 783,426 806,834 Software solutions 72,434 72,185 70,441 Equipment & other 51,944 54,762 61,234 Net revenues $ 908,832 $ 910,373 $ 938,509 Net revenues generated in our principle operating regions are as follows: April 2, March 28, March 29, United States $ 519,440 $ 494,788 $ 500,719 Japan 81,411 88,298 108,679 Europe 187,725 215,575 224,792 Asia 111,758 102,095 94,762 Other 8,498 9,617 9,557 Total $ 908,832 $ 910,373 $ 938,509

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	12 Months Ended
	Apr. 02, 2016
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Transformation Costs by Type of Cost	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and other expense, net in our consolidated statements of (loss) income for the periods presented. Transformation costs (in thousands) 2016 2015 2014 Transformation and other costs $ 17,377 $ 26,979 $ 30,656 Accelerated depreciation 155 930 4,203 Asset disposal 1,697 4,925 796 Total $ 19,229 $ 32,834 $ 35,655 The following summarizes the restructuring activity for the fiscal year ended April 2, 2016 , March 28, 2015 , and March 29, 2014 , respectively: (In thousands) Severance and Other Employee Costs Other Costs Accelerated Depreciation Asset Total Restructuring Balance at March 30, 2013 $ 3,089 $ 173 $ — $ — $ 3,262 Costs incurred 31,492 14,254 2,390 915 49,051 Payments (11,673 ) (13,699 ) — — (25,372 ) Non-cash adjustments — — (2,390 ) (915 ) (3,305 ) Balance at March 29, 2014 $ 22,908 $ 728 $ — $ — $ 23,636 Costs incurred 19,879 15,362 1,326 296 36,863 Payments (26,394 ) (15,871 ) — — (42,265 ) Non-cash adjustments — — (1,326 ) (296 ) (1,622 ) Balance at March 28, 2015 $ 16,393 $ 219 $ — $ — $ 16,612 Costs incurred 10,707 7,846 1,469 3,033 23,055 Payments (18,348 ) (8,065 ) — — (26,413 ) Non-cash adjustments — — (1,469 ) (3,033 ) (4,502 ) Balance at April 2, 2016 $ 8,752 $ — $ — $ — $ 8,752
Restructuring and Related Costs by Segment	The tables below present restructuring and transformation costs by reportable segment: Restructuring costs (in thousands) 2016 2015 2014 Japan $ 9 $ 258 $ 372 EMEA 3,210 3,310 1,444 North America Plasma — 360 42 All Other 19,836 32,935 47,193 Total $ 23,055 $ 36,863 $ 49,051 Transformation costs (in thousands) 2016 2015 2014 Japan $ 416 $ 158 $ 131 EMEA 961 838 1,260 North America Plasma — 28 — All Other 17,852 31,810 34,264 Total $ 19,229 $ 32,834 $ 35,655 Total restructuring and transformation $ 42,284 $ 69,697 $ 84,706

SUMMARY OF QUARTERLY DATA (UN42

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)	12 Months Ended
	Apr. 02, 2016
Quarterly Financial Data [Abstract]
Schedule of Quarterly Data	(In thousands) Three months ended Fiscal 2016 June 27, September 26, December 26, April 2, Net revenues $ 213,413 $ 219,693 $ 233,384 $ 242,342 Gross profit $ 102,539 $ 105,297 $ 108,855 $ 89,223 Operating income (loss) $ 3,606 $ 19,179 $ (61,177 ) $ (5,550 ) Net (loss) income $ (267 ) $ 12,863 $ (59,440 ) $ (8,735 ) Per share data: Net (loss) income: Basic $ (0.01 ) $ 0.25 $ (1.17 ) $ (0.17 ) Diluted $ (0.01 ) $ 0.25 $ (1.17 ) $ (0.17 ) (In thousands) Three months ended Fiscal 2015 June 28, September 27, December 27, March 28, Net revenues $ 224,488 $ 227,580 $ 231,827 $ 226,478 Gross profit $ 106,278 $ 108,114 $ 111,661 $ 108,365 Operating (loss) income $ (1,666 ) $ 12,407 $ 18,260 $ 11,539 Net (loss) income $ (3,649 ) $ 7,487 $ 15,988 $ (2,929 ) Per share data: Net (loss) income: Basic $ (0.07 ) $ 0.15 $ 0.31 $ (0.06 ) Diluted $ (0.07 ) $ 0.14 $ 0.31 $ (0.06 )

ACCUMULATED OTHER COMPREHENSI43

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	12 Months Ended
	Apr. 02, 2016
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended April 2, 2016 and March 28, 2015 : (In thousands) Foreign currency Defined benefit plans Net Unrealized Gain/loss on Derivatives Total Balance as of March 29, 2014 $ 3,198 $ (4,592 ) $ 2,804 $ 1,410 Other comprehensive (loss) income before reclassifications (23,710 ) (4,410 ) 11,371 (16,749 ) Amounts reclassified from accumulated other comprehensive loss — 79 (6,464 ) (6,385 ) Net current period other comprehensive (loss) income (23,710 ) (4,331 ) 4,907 (23,134 ) Balance as of March 28, 2015 $ (20,512 ) $ (8,923 ) $ 7,711 $ (21,724 ) Other comprehensive (loss) income before reclassifications (1,987 ) 884 (3,938 ) (5,041 ) Amounts reclassified from accumulated other comprehensive loss — 547 (8,822 ) (8,275 ) Net current period other comprehensive (loss) income (1,987 ) 1,431 (12,760 ) (13,316 ) Balance as of April 2, 2016 $ (22,499 ) $ (7,492 ) $ (5,049 ) $ (35,040 )
Reclassification out of Accumulated Other Comprehensive Income	The details about the amount reclassified from accumulated other comprehensive loss for the years ended April 2, 2016 and March 28, 2015 are as follows: (In thousands) Amounts Reclassified from Accumulated Other Comprehensive Loss Affected Line in the Statement of (Loss) Income Derivative instruments reclassified to income statement Year ended April 2, 2016 Year ended March 28, 2015 Realized net gain on derivatives $ 8,654 $ 6,736 Net revenues, cost of goods sold, other expense, net Income tax effect 168 (272 ) Provision for income taxes Net of taxes $ 8,822 $ 6,464 Pension items reclassified to income statement Realized net loss on pension assets $ 602 $ 123 Other expense, net Income tax effect (55 ) (44 ) Provision for income taxes Net of taxes $ 547 $ 79

SUMMARY OF SIGNIFICANT ACCOUN44

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2016USD ($)	Apr. 02, 2016USD ($)Customers	Mar. 28, 2015USD ($)Customers	Mar. 29, 2014USD ($)Customers
Summary of Significant Accounting Pronouncements [Line Items]
Cash and cash equivalents maximum maturity period		3 months
Goodwill impairment	$ 66,300	$ 66,305
Intangible asset impairment		25,800
Impairment charges related to the discontinuance of certain capitalized software projects	6,000
Other Liabilities
VAT liabilities	1,289	1,289	$ 4,205
Forward contracts	4,210	4,210	2,657
Deferred revenue	27,053	27,053	22,362
Accrued taxes	3,876	3,876	3,819
All other	30,180	30,180	34,579
Total	66,608	66,608	67,622
Other Long-Term Liabilities
Unfunded pension liability	18,067	18,067	17,402
Unrecognized tax benefit	2,283	2,283	3,992
All other	5,756	5,756	10,343
Total	$ 26,106	26,106	31,737
Advertising expense		3,900	4,500	$ 3,600
Foreign currency losses		$ 1,400	1,100	$ 500
New Accounting Pronouncement, Early Adoption, Effect [Member]
Other Long-Term Liabilities
Current deferred tax assets			12,600
Current deferred tax liabilities			$ 400
Building
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		30 years
Sales [Member] | Customer Concentration Risk [Member]
Other Long-Term Liabilities
Concentration risk, number of customers | Customers		0	0	0
Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		5 years
Minimum | Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		5 years
Minimum | Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		3 years
Minimum | Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		2 years
Minimum | Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		3 years
Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term		10 years
Maximum | Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		20 years
Maximum | Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		15 years
Maximum | Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		10 years
Maximum | Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life		7 years
SOLX Intangible Assets [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Intangible asset impairment		$ 18,700
Other Intangible Assets [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Intangible asset impairment		$ 7,100

PRODUCT WARRANTIES (Schedule of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015
Product Warranties Disclosures [Abstract]
General warranty period on parts and labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the year	$ 531	$ 590
Warranty provision	948	1,199
Warranty spending	(1,059)	(1,258)
Warranty accrual as of the end of the year	$ 420	$ 531

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Mar. 28, 2015
Inventory [Line Items]
Raw materials	$ 62,062	$ 71,794
Work-in-process	13,180	12,462
Finished goods	111,786	126,821
Total Inventories	187,028	$ 211,077
Inventory charges and reserves recorded	9,400
Blood Center Products [Member]
Inventory [Line Items]
Inventory charges and reserves recorded	$ 5,300

GOODWILL AND INTANGIBLE ASSET47

GOODWILL AND INTANGIBLE ASSETS Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2013	Apr. 02, 2016	Dec. 26, 2015	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 267,840		$ 267,840	$ 334,310	$ 336,768
Goodwill impairment		66,300		66,305
Intangible asset impairment				25,800
Impairment charges related to the discontinuance of certain capitalized software projects		6,000
Changes in fair value of contingent consideration				$ 4,727	$ 2,918	(45)
Weighted average useful life				10 years	10 years
Aggregate amortization expense				$ 59,300	$ 33,500	29,200
Asset Impairments [Member]
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense				$ 25,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life				2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life				19 years
Americas Blood Center and Hospital [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of fair value in excess of carrying amount			25.80%
Goodwill			$ 175,900
EMEA
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 0		$ 0	72,695	$ 74,019
Goodwill impairment				66,305
Intangible asset impairment				6,600
All Other
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment				19,200
SOLX Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	$ 24,100
Intangible asset impairment				18,700
Changes in fair value of contingent consideration			$ 4,900	4,900	$ 2,900
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment				7,100
Cost of Goods Sold [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment				6,600
Impairment of Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment				$ 19,200

GOODWILL AND INTANGIBLE ASSET48

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Apr. 02, 2016	Mar. 28, 2015
Goodwill [Roll Forward]
Goodwill, carrying amount		$ 334,310	$ 336,768
Currency translation		(165)	(2,458)
Impairment charge	$ (66,300)	(66,305)
Transfer of goodwill between segments		0
Goodwill, carrying amount	267,840	267,840	334,310
Japan
Goodwill [Roll Forward]
Goodwill, carrying amount		24,899	25,477
Currency translation		(16)	(578)
Impairment charge		0
Transfer of goodwill between segments		0
Goodwill, carrying amount	24,883	24,883	24,899
EMEA
Goodwill [Roll Forward]
Goodwill, carrying amount		72,695	74,019
Currency translation		0	(1,324)
Impairment charge		(66,305)
Transfer of goodwill between segments		(6,390)
Goodwill, carrying amount	0	0	72,695
North America Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount		26,415	26,415
Currency translation		0	0
Impairment charge		0
Transfer of goodwill between segments		0
Goodwill, carrying amount	26,415	26,415	26,415
All Other
Goodwill [Roll Forward]
Goodwill, carrying amount		210,301	210,857
Currency translation		(149)	(556)
Impairment charge		0
Transfer of goodwill between segments		6,390
Goodwill, carrying amount	$ 216,542	$ 216,542	$ 210,301

GOODWILL AND INTANGIBLE ASSET49

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015
Amortizable:
Gross Carrying Amount	$ 378,343	$ 367,104
Accumulated Amortization	190,816	133,175
Net	187,527	233,929
Non-amortizable intangibles	$ 16,931	$ 10,659
Weighted average useful life	10 years	10 years
Future amortization expense, year one	$ 31,397
Future amortization expense, year two	30,959
Future amortization expense, year three	29,250
Future amortization expense, year four	27,353
Future amortization expense, year five	25,512
In-process software development
Amortizable:
Non-amortizable intangibles	14,427	$ 7,872
In-process patents
Amortizable:
Non-amortizable intangibles	2,504	2,787
Patents
Amortizable:
Gross Carrying Amount	8,545	7,686
Accumulated Amortization	7,542	7,373
Net	$ 1,003	$ 313
Weighted average useful life	9 years	9 years
Capitalized software
Amortizable:
Gross Carrying Amount	$ 40,488	$ 31,818
Accumulated Amortization	14,791	5,654
Net	$ 25,697	$ 26,164
Weighted average useful life	6 years	7 years
Other developed technology
Amortizable:
Gross Carrying Amount	$ 126,142	$ 124,573
Accumulated Amortization	73,475	46,474
Net	$ 52,667	$ 78,099
Weighted average useful life	12 years	12 years
Customer contracts and related relationships
Amortizable:
Gross Carrying Amount	$ 196,085	$ 195,985
Accumulated Amortization	89,804	70,440
Net	$ 106,281	$ 125,545
Weighted average useful life	10 years	10 years
Trade names
Amortizable:
Gross Carrying Amount	$ 7,083	$ 7,042
Accumulated Amortization	5,204	3,234
Net	$ 1,879	$ 3,808
Weighted average useful life	11 years	11 years

DERIVATIVES AND FAIR VALUE ME50

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) $ in Thousands	Aug. 01, 2012	Dec. 26, 2015USD ($)	Apr. 02, 2016USD ($)	Mar. 28, 2015USD ($)	Mar. 29, 2014USD ($)	Dec. 21, 2012USD ($)swap
Derivative [Line Items]
Deferred tax benefit			$ (1,031)	$ 4,230	$ (202)
Variable rate basis	LIBOR		LIBOR index of 1-month, 3-months, 6-months, etc
Changes in fair value of contingent consideration			$ 4,727	2,918	(45)
Term Loan
Derivative [Line Items]
Adjusted libor rounding percentage	6.25%
Credit Agreement
Derivative [Line Items]
Adjusted libor rounding percentage	0.625%
Variable rate basis	1-month USD-LIBOR-BBA
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US			42.90%
Maturity period for foreign currency contracts (in years)			1 year
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding			$ 107,400	145,800
Deferred tax benefit			300
Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)				(900)	1,300
Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Gain (loss) on cash flow hedge in earnings			8,800	6,500	8,600
Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps held | swap						2
Derivative, Fixed Interest Rate						0.68%
Derivative, Notional Amount						$ 250,000
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)			0
Non-designated foreign currency hedge contracts outstanding			48,800	52,600
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] | Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)			(3,940)	12,200	$ 3,700
Other expense, net | Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)			2
SOLX Intangible Assets [Member]
Derivative [Line Items]
Changes in fair value of contingent consideration		$ 4,900	$ 4,900	$ 2,900

DERIVATIVES AND FAIR VALUE ME51

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Designated as Hedging Instrument | Foreign Exchange Contract | Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (3,940)	$ 12,200	$ 3,700
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	8,822
Designated as Hedging Instrument | Foreign Exchange Contract | Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	102
Designated as Hedging Instrument | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)		$ (900)	$ 1,300
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument | Interest Rate Swap | Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	2
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	0
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract | Other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ (203)

DERIVATIVES AND FAIR VALUE ME52

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands	Apr. 02, 2016	Mar. 28, 2015
Derivative Assets:
Derivative Assets	$ 427	$ 9,740
Derivative Liabilities:
Derivative Liabilities	4,210	2,658
Foreign Exchange Contract | Other Current Assets
Derivative Assets:
Derivative Assets	427	9,740
Foreign Exchange Contract | Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	4,056	2,499
Interest Rate Swap | Other Current Assets
Derivative Assets:
Derivative Assets	0	0
Interest Rate Swap | Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 154	$ 159

DERIVATIVES AND FAIR VALUE ME53

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015
Assets
Money market funds	$ 72,491	$ 119,946
Foreign currency hedge contracts	427	9,740
Assets, Fair Value Disclosure, Total	72,918	129,686
Liabilities
Foreign currency hedge contracts	4,056	2,499
Interest rate swap	154	159
Contingent consideration	0	4,727
Liabilities, Fair Value Disclosure, Total	4,210	7,385
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	72,491	119,946
Foreign currency hedge contracts	0	0
Assets, Fair Value Disclosure, Total	72,491	119,946
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0	0
Contingent consideration	0	0
Liabilities, Fair Value Disclosure, Total	0	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0	0
Foreign currency hedge contracts	427	9,740
Assets, Fair Value Disclosure, Total	427	9,740
Liabilities
Foreign currency hedge contracts	4,056	2,499
Interest rate swap	154	159
Contingent consideration	0	0
Liabilities, Fair Value Disclosure, Total	4,210	2,658
Significant Unobservable Inputs (Level 3)
Assets
Money market funds	0	0
Foreign currency hedge contracts	0	0
Assets, Fair Value Disclosure, Total	0	0
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0	0
Contingent consideration	0	4,727
Liabilities, Fair Value Disclosure, Total	0	$ 4,727
Contingent consideration
Balance at March 28, 2015	4,727
Fair value adjustment	(4,727)
Balance at April 2, 2016	$ 0

NOTES PAYABLE AND LONG-TERM D54

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Apr. 02, 2016	Mar. 28, 2015
Debt Instrument [Line Items]
Long-term debt	$ 408,465
Less current portion	(43,471)	$ (21,522)
Long term debt	364,529	406,369
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt	406,175	426,814
Mortgage Obligation
Debt Instrument [Line Items]
Long-term debt	0	851
Bank loans and other borrowings
Debt Instrument [Line Items]
Long-term debt	$ 1,825	$ 226

NOTES PAYABLE AND LONG-TERM D55

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) $ in Thousands	Aug. 01, 2012USD ($)	Dec. 31, 2000USD ($)	Apr. 02, 2016USD ($)	Mar. 28, 2015USD ($)	Mar. 29, 2014USD ($)	Jun. 30, 2014USD ($)	Dec. 02, 2000USD ($)
Debt Instrument [Line Items]
Variable rate basis	LIBOR		LIBOR index of 1-month, 3-months, 6-months, etc
Interest paid			$ 8,511	$ 8,497	$ 8,942
Interest payable			100
Long-term debt			408,465
Term Loan
Debt Instrument [Line Items]
Face amount of debt			408,100
Adjusted libor rounding percentage	6.25%
Basis spread on variable rate	1.375%
Amount outstanding			$ 358,100
Effective interest rate			1.90%
Debt discount			$ (1,900)
Term Loan | Pall Corporation [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 475,000
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt			$ 406,175	426,814
Revolving Credit Facility
Debt Instrument [Line Items]
Face amount of debt	$ 50,000
Term of debt	5 years
Maximum borrowing capacity						$ 100,000
Consolidated total leverage ratio			3
Consolidated interest coverage ratio			4
Commitment fee			0.25%
Long-term debt			$ 50,000
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Commitment fee			0.175%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Commitment fee			0.30%
Credit Agreement
Debt Instrument [Line Items]
Variable rate basis	1-month USD-LIBOR-BBA
Adjusted libor rounding percentage	0.625%
Credit Agreement | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Effective interest rate			1.875%
Credit Agreement | London Interbank Offered Rate (LIBOR) [Member] | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%
Credit Agreement | London Interbank Offered Rate (LIBOR) [Member] | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Mortgage Obligation
Debt Instrument [Line Items]
Face amount of debt							$ 10,000
Long-term debt			$ 0	$ 851
Monthly principal and interest payments		$ 100

NOTES PAYABLE AND LONG-TERM D56

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) $ in Thousands	Apr. 02, 2016USD ($)
Debt Instrument [Line Items]
2,017	$ 42,837
2,018	45,162
2,019	151,852
2,020	168,614
Long-term debt	408,465
Credit Facilities
Debt Instrument [Line Items]
2,017	42,683
2,018	45,054
2,019	151,763
2,020	168,564
Long-term debt	408,064
Bank loans and other borrowings
Debt Instrument [Line Items]
2,017	154
2,018	108
2,019	89
2,020	50
Long-term debt	$ 401

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Income Taxes [Line Items]
Benefit to income taxes relating to the impairments of goodwill, intangibles, and fixed assets	$ 7,100
Foregin source income	(34,890)	$ 48,430	$ 43,260
Valuation allowance	5,194	8,524	$ 2,400
Tax credit carry-forward, net	$ 16,191	$ 8,678
Income tax provision	(4.00%)	45.80%	3.40%
Unremitted earnings which are not indefinitely reinvested	$ 5,400
Amount of unremitted earnings affecting tax rate	300
Undistributed foreign earnings of subsidiaries	$ 254,100
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
Unremitted earnings	$ 735	$ 0	$ 0
Provision for income taxes	2,163	14,268	1,253
Unrecognized tax benefits	2,523	7,070	5,604	$ 6,930
Unrecognized tax benefits that will impact effective tax rate	600	2,000
Unrecognized tax benefits, increases from closure of statute of limitations	(4,500)
Unrecognized tax positions possible change in the next twelve months	400
Accrued interest and penalties	400	700
Accrued interest on income tax benefit	300	$ 300	$ 0
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Valuation allowance	8,300
Operating loss carry-forwards	29,200
Tax credit carry-forward, net	13,700
Domestic Tax Authority [Member] | Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	4,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	33,100
Tax credit carry-forward, net	3,800
State and Local Jurisdiction [Member] | Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	5,300
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	25,200
Foreign Tax Authority [Member] | Expire 2023 [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	12,200
Foreign Tax Authority [Member] | Expire 2025 [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	$ 100
Puerto Rico
Income Taxes [Line Items]
Tax grant or holiday term	15 years
Switzerland
Income Taxes [Line Items]
Tax grant or holiday term	10 years

INCOME TAXES (Schedule Domestic

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Income Tax Disclosure [Abstract]
Domestic	$ (18,526)	$ (17,265)	$ (6,859)
Foreign	(34,890)	48,430	43,260
(Loss) income before provision for income taxes	$ (53,416)	$ 31,165	$ 36,401

INCOME TAXES (Schedule of Incom

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Current
Federal	$ 12	$ 3,526	$ (4,896)
State	(660)	898	873
Foreign	3,842	5,614	5,478
Total current	3,194	10,038	1,455
Deferred
Federal	3,532	1,227	(1,785)
State	319	3,215	207
Foreign	(4,882)	(212)	1,376
Total deferred	(1,031)	4,230	(202)
Total	$ 2,163	$ 14,268	$ 1,253

INCOME TAXES (Schedule of Net D

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Apr. 02, 2016	Mar. 28, 2015
Income Tax Disclosure [Abstract]
Depreciation	$ 1,749	$ 609
Amortization of intangibles	4,417	727
Inventory	7,607	6,193
Hedging	382	84
Accruals, reserves and other deferred tax assets	12,590	17,526
Net operating loss carry-forward	13,484	5,392
Stock based compensation	9,622	10,652
Tax credit carry-forward, net	16,191	8,678
Gross deferred tax assets	66,042	49,861
Total deferred tax liabilities	(24,297)	(16,027)
Total deferred tax assets (after valuation allowance)	41,745	33,834
Depreciation	(28,972)	(24,342)
Amortization of goodwill and intangibles	(23,626)	(24,764)
Unremitted earnings	(700)	0
Other deferred tax liabilities	(2,769)	(1,604)
Other deferred tax liabilities	(56,067)	(50,710)
Net deferred tax liabilities	$ (14,322)	$ (16,876)

INCOME TAXES (Schedule of Effec

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ (18,695)	$ 10,907	$ 12,739
Tax at federal statutory rate	35.00%	35.00%	35.00%
Difference between U.S. and foreign tax	$ 10,645	$ (6,929)	$ (10,846)
Difference between U.S. and foreign tax	(19.90%)	(22.20%)	(29.80%)
State income taxes net of federal benefit	$ 134	$ (818)	$ (252)
State income taxes net of federal benefit	(0.30%)	(2.60%)	(0.70%)
Change in uncertain tax positions	$ (1,820)	$ (1,762)	$ (1,678)
Change in uncertain tax positions	3.40%	(5.70%)	(4.60%)
Intercompany loan deduction	$ 0	$ 0	$ (2,185)
Intercompany loan deduction	(0.00%)	(0.00%)	(6.00%)
Unremitted earnings	$ 735	$ 0	$ 0
Unremitted earnings	(1.40%)	(0.00%)	(0.00%)
Deferred statutory rate changes	$ (2,653)	$ 0	$ 0
Deferred statutory rate changes	5.00%	0.00%	0.00%
Non-deductible goodwill impairment	$ 2,861	$ 0	$ 0
Non-deductible goodwill impairment	(5.40%)	(0.00%)	(0.00%)
Non-deductible expenses	$ 1,491	$ 1,237	$ 1,035
Non-deductible expenses	(2.80%)	4.00%	2.80%
Research credits	$ (672)	$ (1,000)	$ (688)
Research credits	1.30%	(3.20%)	(1.90%)
Tax amortization of goodwill	$ 4,185	$ 3,826	$ 0
Tax amortization of goodwill	(7.80%)	12.30%	0.00%
Valuation allowance	$ 5,194	$ 8,524	$ 2,400
Valuation allowance	(9.70%)	27.40%	6.60%
Other, net	$ 758	$ 283	$ 728
Other, net	(1.40%)	0.80%	2.00%
Total	$ 2,163	$ 14,268	$ 1,253
Income tax provision	(4.00%)	45.80%	3.40%

INCOME TAXES (Summary of Gross

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 7,070	$ 5,604	$ 6,930
Additions based upon positions related to the current year	0	0	0
Additions for tax positions of prior years	340	3,234	990
Reductions of tax positions	(4,158)	0	0
Settlements with taxing authorities	0	(338)	0
Closure of statute of limitations	(729)	(1,430)	(2,316)
Ending Balance	$ 2,523	$ 7,070	$ 5,604

COMMITMENTS AND CONTINGENCIES63

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) $ in Thousands	Apr. 02, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 4,845
2,018	3,830
2,019	2,476
2,020	1,820
2,021	1,708
Thereafter	6,143
Operating Leases, Future Minimum Payments Due	$ 20,822

COMMITMENTS AND CONTINGENCIES64

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Loss Contingencies [Line Items]
Rent expense	$ 6.8	$ 6.3	$ 7.7
Italian Employment Litigation
Loss Contingencies [Line Items]
Damages sought	$ 4.6

CAPITAL STOCK (Narrative) (Deta

CAPITAL STOCK (Narrative) (Details)	12 Months Ended
	Apr. 02, 2016USD ($)Members$ / sharesshares	Mar. 28, 2015USD ($)PurchasePeriods$ / sharesshares	Mar. 29, 2014USD ($)$ / shares	Mar. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	6,037,933
Income tax benefit recognized related to stock-based compensation | $	$ 0	$ 4,500,000	$ 4,300,000
Excess cash tax benefit classified as a financing cash inflow | $	$ 0	$ 1,600,000	$ 2,400,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	1,400,000
Number of purchase periods (in purchase periods) | PurchasePeriods		2
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) | $ / shares	$ 7.80	$ 7.09	$ 8.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6 months	6 months	6 months
Employee Stock Purchase Plan [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	2.00%
Employee Stock Purchase Plan [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	15.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	2,951,183	3,761,666
Award expiration period	7 years
Total intrinsic value of options exercised | $	$ 4,500,000	$ 5,600,000	$ 11,700,000
Total unrecognized compensation cost related to non vested awards | $	$ 4,500,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 9 months 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Stock Options [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Stock Options [Member] | Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	380,871	357,547
Total unrecognized compensation cost related to non vested awards | $	$ 9,500,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 5 months 16 days
Weighted Average Grant Date Fair Value (in dollars per share), Granted | $ / shares	$ 33.19	$ 34.89	$ 42.24
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Restricted Stock Units (RSUs) [Member] | Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	204,672
Equity instruments other than options outstanding (in shares)	102,336	129,130
Total unrecognized compensation cost related to non vested awards | $	$ 2,700,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 2 months 16 days
Award performance period	3 years
Performance shares target, percentage	100.00%
Weighted Average Grant Date Fair Value (in dollars per share), Granted | $ / shares	$ 29.20	$ 35.09
Performance Share Units (PSUs) [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	0.00%
Performance Share Units (PSUs) [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	200.00%
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	458,904
Equity instruments other than options outstanding (in shares)	152,968	287,682
Total unrecognized compensation cost related to non vested awards | $	$ 1,800,000
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	1 year
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	1 year 7 months 28 days	2 years 9 months 15 days	3 years 8 months 12 days
Weighted Average Grant Date Fair Value (in dollars per share), Granted | $ / shares	$ 10.21	$ 7.44	$ 36.36
Market Stock Units [Member] | Minimum Threshold Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price | $ / shares	50
Market Stock Units [Member] | Three Times Target Amount, Minimum Price or Higher [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price | $ / shares	$ 85
Incentive Compensation Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of members on board of directors (in board members) | Members	3
Maximum number of shares available for award (in shares)	19,824,920
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.02
Incentive Compensation Plan 2005 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	500,000
Number of options counted against maximum number of award shares for every share option issued (in shares)	1

CAPITAL STOCK (Schedule of Stoc

CAPITAL STOCK (Schedule of Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 6,949	$ 14,095	$ 13,082
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	5,183	11,251	10,507
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	1,060	1,706	1,545
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 706	$ 1,138	$ 1,030

CAPITAL STOCK (Schedule of Summ

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	3,761,666
Options Outstanding, (in shares), Granted	409,047
Options Outstanding, (in shares), Exercised	(491,546)
Options Outstanding, (in shares), Forfeited	(727,984)
Options Outstanding, (in shares), Ending Balance	2,951,183	3,761,666
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 33.90
Weighted Average Exercise Price (in dollars per share), Granted	32.50
Weighted Average Exercise Price (in dollars per share), Exercised	28.55
Weighted Average Exercise Price (in dollars per share), Forfeited	37.98
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 33.59	$ 33.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	3 years 4 months 2 days	4 years 7 days
Aggregate Intrinsic Value, Balance	$ 9,684	$ 37,067
Options Outstanding, (in shares), Exercisable and End of Period	2,288,166
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 33.22
Weighted Average Remaining Life, Exercisable at End of Period	2 years 7 months 2 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 8,428
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	2,847,285
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 33.56
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years 2 months 16 days
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 9,432

CAPITAL STOCK (Schedule of Assu

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value) (Details) - $ / shares	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility		21.10%	23.70%	22.90%
Expected term		6 months	6 months	6 months
Risk-free interest rate		0.20%	0.10%	0.10%
Dividend Yield		0.00%	0.00%	0.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	22.80%	22.50%	24.80%
Expected term	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	1.40%	1.50%	1.30%
Dividend Yield	0.00%	0.00%	0.00%
Fair value per option (in dollars per share)	$ 7.40	$ 7.91	$ 10.15
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value (in dollars per share), Granted	33.19	34.89	42.24
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 36.07	$ 36.62	$ 32.70
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	22.27%	20.08%
Peer group stock price volatility	31.95%	31.52%
Correlation of returns	26.27%	30.52%
Weighted Average Grant Date Fair Value (in dollars per share), Granted	$ 29.20	$ 35.09
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 0
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	24.00%	21.20%	20.20%
Expected term	1 year 7 months 28 days	2 years 9 months 15 days	3 years 8 months 12 days
Risk-free interest rate	0.50%	0.80%	0.90%
Dividend Yield	0.00%	0.00%	0.00%
Weighted Average Grant Date Fair Value (in dollars per share), Granted	$ 10.21	$ 7.44	$ 36.36
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 0

CAPITAL STOCK (Schedule of Su69

CAPITAL STOCK (Schedule of Summary of Equity Awards other than Options Activity) (Details) - $ / shares	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	357,547
Shares, Granted (in shares)	278,260
Shares, Vested (in shares)	(112,333)
Shares, Forfeited (in shares)	(142,603)
Shares, Ending Balance (in shares)	380,871	357,547
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 36.73
Weighted Average Grant Date Fair Value (in dollars per share), Granted	33.19	$ 34.89	$ 42.24
Weighted Average Grant Date Fair Value (in dollars per share), Vested	36.07	36.62	32.70
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	36.72
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 34.33	$ 36.73
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	129,130
Shares, Granted (in shares)	80,145
Shares, Vested (in shares)	0
Shares, Forfeited (in shares)	(106,939)
Shares, Ending Balance (in shares)	102,336	129,130
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 35.09
Weighted Average Grant Date Fair Value (in dollars per share), Granted	29.20	$ 35.09
Weighted Average Grant Date Fair Value (in dollars per share), Vested	0
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	34.22
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 31.38	$ 35.09
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	287,682
Shares, Granted (in shares)	33,550
Shares, Vested (in shares)	0
Shares, Forfeited (in shares)	(168,264)
Shares, Ending Balance (in shares)	152,968	287,682
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 33.90
Weighted Average Grant Date Fair Value (in dollars per share), Granted	10.21	$ 7.44	$ 36.36
Weighted Average Grant Date Fair Value (in dollars per share), Vested	0
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	37.42
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 24.84	$ 33.90

EARNINGS PER SHARE ("EPS") (Sch

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Basic EPS
Net (loss) income	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ (55,579)	$ 16,897	$ 35,148
Basic weighted average shares (in shares)									50,910	51,533	51,611
Basic (loss) income per share (in dollars per share)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.06)	$ 0.31	$ 0.15	$ (0.07)	$ (1.09)	$ 0.33	$ 0.68
Diluted EPS
Net (loss) income	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ (55,579)	$ 16,897	$ 35,148
Basic weighted average shares (in shares)									50,910	51,533	51,611
Net effect of common stock equivalents (in shares)									0	556	766
Diluted weighted average shares (in shares)									50,910	52,089	52,377
Diluted (loss) income per share (in dollars per share)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.06)	$ 0.31	$ 0.14	$ (0.07)	$ (1.09)	$ 0.32	$ 0.67
Stock options and restricted share units excluded from computation of weighted average shares outstanding (in shares)										1,600	1,100

PROPERTY, PLANT AND EQUIPMENT71

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Property, Plant and Equipment [Line Items]
Total	$ 786,458	$ 731,762
Less: accumulated depreciation and amortization	(448,824)	(409,814)
Net property, plant and equipment	337,634	321,948
Impairment of property, plant and equipment	9,100
Depreciation expense	56,800	52,600	$ 52,600
Asset Reclassified to Held for Sale [Member]
Property, Plant and Equipment [Line Items]
Net property, plant and equipment	1,700
Impairment of property, plant and equipment	3,000
Asset Impairments [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	800
Impairment of Assets [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	6,900
Cost of Goods Sold [Member]
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	2,200
Land
Property, Plant and Equipment [Line Items]
Total	7,905	9,468
Building and building improvements
Property, Plant and Equipment [Line Items]
Total	117,132	118,384
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Total	238,549	220,793
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Total	127,019	118,810
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Total	295,853	$ 264,307
All Other
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	$ 6,100

RETIREMENT PLANS (Narrative) (D

RETIREMENT PLANS (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation, plan funded by company	$ 8,700	$ 9,200
Benefit obligation	(37,919)	(40,567)	$ (32,621)
Accumulated benefit obligation	36,400	34,900
Fair value of plan assets	19,852	23,165	19,981
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	200
Subsidiaries [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	800	1,000	800
Savings Plus Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 5,400	$ 5,800	$ 6,200

RETIREMENT PLANS (Schedule of C

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 3,560	$ 2,979	$ 3,351
Interest cost on benefit obligation	371	686	623
Expected (return)/loss on plan assets	(330)	(449)	(435)
Actuarial loss/(gain)	598	107	88
Amortization of unrecognized prior service cost	(38)	(29)	182
Amortization of unrecognized transition obligation	42	45	47
Totals	$ 4,203	$ 3,339	$ 3,856

RETIREMENT PLANS (Schedule of A

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (40,567)	$ (32,621)
Service cost	(3,560)	(2,979)	$ (3,351)
Interest cost	(371)	(686)	(623)
Benefits paid	3,780	4,902
Actuarial (loss)/gain	424	(6,883)
Employee and plan participants contribution	(1,839)	(2,978)
Plan Amendments	833	114
Foreign currency changes	3,381	564
Benefit obligation, end of year	(37,919)	(40,567)	(32,621)
Change in Plan Assets:
Fair value of plan assets, beginning of year	23,165	19,981
Company contributions	1,987	2,112
Benefits paid	(3,779)	(4,621)
Gain/(Loss) on plan assets	446	506
Employee and plan participants contributions	1,861	2,851
Foreign currency changes	(3,828)	2,336
Fair value of Plan Assets, end of year	19,852	23,165	$ 19,981
Funded Status	(18,067)	(17,402)
Unrecognized net actuarial loss/(gain)	10,168	11,096
Unrecognized initial obligation	37	64
Unrecognized prior service cost	(1,186)	(459)
Net amount recognized	$ (9,048)	$ (6,701)

RETIREMENT PLANS (Schedule of75

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (8,923)	$ (4,592)	$ (5,073)
Obligation at transition	33	(19)	172
Actuarial loss	681	(6,198)	(129)
Prior service cost	717	1,886	438
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (7,492)	$ (8,923)	$ (4,592)

RETIREMENT PLANS (Schedule of W

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Compensation and Retirement Disclosure [Abstract]
Discount rate	0.72%	0.93%	2.02%
Rate of increased salary levels	1.58%	1.65%	1.57%
Expected long-term rate of return on assets	1.20%	1.68%	1.94%

RETIREMENT PLANS (Schedule of E

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Apr. 02, 2016USD ($)
Expected Benefit Payments
Fiscal Year 2017	$ 1,746
Fiscal Year 2018	1,542
Fiscal Year 2019	1,523
Fiscal Year 2020	1,883
Fiscal Year 2021	1,687
Fiscal Year 2022-2026	7,872
Total	$ 16,253

SEGMENT AND ENTERPRISE-WIDE I78

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 02, 2016USD ($)	Dec. 26, 2015USD ($)	Sep. 26, 2015USD ($)	Jun. 27, 2015USD ($)	Mar. 28, 2015USD ($)	Dec. 27, 2014USD ($)	Sep. 27, 2014USD ($)	Jun. 28, 2014USD ($)	Apr. 02, 2016USD ($)segment	Mar. 28, 2015USD ($)	Mar. 29, 2014USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment									2
Segment Reporting Information [Line Items]
Net revenues (constant currency)									$ 910,515	$ 883,832	$ 896,080
Effect of exchange rates									(1,683)	26,541	42,429
Net revenues (reported)	$ 242,342	$ 233,384	$ 219,693	$ 213,413	$ 226,478	$ 231,827	$ 227,580	$ 224,488	908,832	910,373	938,509
Segment operating income (constant currency)									310,088	313,464	324,654
Corporate operating expenses (constant currency)									(194,361)	(189,867)	(186,562)
Non-GAAP operating income (constant currency)									115,727	123,597	138,092
Effect of exchange rates									3,977	13,906	21,147
Non-GAAP operating income (reported)									119,704	137,503	159,239
Restructuring and transformation costs									42,185	69,697	84,706
Deal amortization									28,958	30,184	28,056
Impairment of assets									97,230	0	0
Contingent consideration (income) expense									(4,727)	(2,918)	45
Operating (loss) income	(5,550)	$ (61,177)	$ 19,179	$ 3,606	11,539	$ 18,260	$ 12,407	$ (1,666)	(43,942)	40,540	46,432
Depreciation and amortization									89,911	86,053	81,740
Long-lived assets	337,634				321,948				337,634	321,948	271,437
Plasma disposables
Segment Reporting Information [Line Items]
Net revenues (reported)									348,785	319,190	291,895
Blood center disposables
Segment Reporting Information [Line Items]
Net revenues (reported)									311,062	339,193	389,719
Platelet
Segment Reporting Information [Line Items]
Net revenues (reported)									143,274	152,588	156,643
Red cell
Segment Reporting Information [Line Items]
Net revenues (reported)									39,256	42,700	42,378
Whole blood
Segment Reporting Information [Line Items]
Net revenues (reported)									128,532	143,905	190,698
Hospital disposables
Segment Reporting Information [Line Items]
Net revenues (reported)									124,607	125,043	125,220
Surgical
Segment Reporting Information [Line Items]
Net revenues (reported)									59,902	62,540	66,876
OrthoPAT
Segment Reporting Information [Line Items]
Net revenues (reported)									13,823	20,316	25,042
Diagnostics
Segment Reporting Information [Line Items]
Net revenues (reported)									50,882	42,187	33,302
Disposables revenue
Segment Reporting Information [Line Items]
Net revenues (reported)									784,454	783,426	806,834
Software solutions
Segment Reporting Information [Line Items]
Net revenues (reported)									72,434	72,185	70,441
Equipment & other
Segment Reporting Information [Line Items]
Net revenues (reported)									51,944	54,762	61,234
United States
Segment Reporting Information [Line Items]
Net revenues (reported)									519,440	494,788	500,719
Long-lived assets	231,744				208,439				231,744	208,439	185,227
Japan
Segment Reporting Information [Line Items]
Net revenues (reported)									81,411	88,298	108,679
Long-lived assets	2,022				1,618				2,022	1,618	2,563
Europe
Segment Reporting Information [Line Items]
Net revenues (reported)									187,725	215,575	224,792
Long-lived assets	18,672				27,786				18,672	27,786	37,154
Asia
Segment Reporting Information [Line Items]
Net revenues (reported)									111,758	102,095	94,762
Long-lived assets	40,235				39,032				40,235	39,032	8,785
Other
Segment Reporting Information [Line Items]
Net revenues (reported)									8,498	9,617	9,557
Long-lived assets	44,961				45,073				44,961	45,073	37,708
Japan
Segment Reporting Information [Line Items]
Net revenues (constant currency)									84,270	83,547	89,041
Segment operating income (constant currency)									37,165	36,843	38,685
Depreciation and amortization									774	767	839
Long-lived assets	33,159				31,810				33,159	31,810	28,544
EMEA
Segment Reporting Information [Line Items]
Net revenues (constant currency)									175,874	183,753	193,691
Segment operating income (constant currency)									36,976	44,998	49,373
Depreciation and amortization									5,146	5,045	4,695
Long-lived assets	63,861				66,223				63,861	66,223	59,034
North America Plasma
Segment Reporting Information [Line Items]
Net revenues (constant currency)									279,803	240,705	213,215
Segment operating income (constant currency)									100,367	89,092	82,497
Depreciation and amortization									12,944	11,229	8,776
Long-lived assets	116,001				101,272				116,001	101,272	75,597
All Other
Segment Reporting Information [Line Items]
Net revenues (constant currency)									370,568	375,827	400,133
Segment operating income (constant currency)									135,580	142,531	154,099
Depreciation and amortization									71,047	69,012	67,430
Long-lived assets	$ 124,613				$ 122,643				$ 124,613	$ 122,643	$ 108,262

RESTRUCTURING (Narrative) (Deta

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 26, 2015	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Restructuring Cost and Reserve [Line Items]
Impairment of property, plant and equipment		$ 9,100
Expected cost		26,000
Expected savings		40,000
Restructuring charges incurred		23,055	$ 36,863	$ 49,051
Restructuring charges in next twelve months		8,100
Restructuring liability		8,752	16,612	23,636	$ 3,262
Transformation costs		19,229	32,834	35,655
Changes in fair value of contingent consideration		4,727	2,918	(45)
Asset Reclassified to Held for Sale [Member]
Restructuring Cost and Reserve [Line Items]
Impairment of property, plant and equipment		3,000
SOLX Intangible Assets [Member]
Restructuring Cost and Reserve [Line Items]
Changes in fair value of contingent consideration	$ 4,900	4,900	2,900
Severance and other employee costs
Restructuring Cost and Reserve [Line Items]
Expected cost		17,000
Restructuring charges incurred		10,707	19,879	31,492
Restructuring liability		8,752	16,393	22,908	3,089
Other costs
Restructuring Cost and Reserve [Line Items]
Expected cost		9,000
Restructuring charges incurred		7,846	15,362	14,254
Restructuring liability		0	$ 219	$ 728	$ 173
VCC Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		$ 100,100

RESTRUCTURING (Schedule of Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 16,612	$ 23,636	$ 3,262
Cost Incurred	23,055	36,863	49,051
Payments	(26,413)	(42,265)	(25,372)
Non-cash adjustments	(4,502)	(1,622)	(3,305)
Ending Balance	8,752	16,612	23,636
Transformation costs	19,229	32,834	35,655
Total restructuring and transformation	42,284	69,697	84,706
Transformation and other costs
Restructuring Reserve [Roll Forward]
Transformation costs	17,377	26,979	30,656
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Transformation costs	155	930	4,203
Asset disposal
Restructuring Reserve [Roll Forward]
Transformation costs	1,697	4,925	796
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Beginning Balance	16,393	22,908	3,089
Cost Incurred	10,707	19,879	31,492
Payments	(18,348)	(26,394)	(11,673)
Non-cash adjustments	0	0	0
Ending Balance	8,752	16,393	22,908
Other costs
Restructuring Reserve [Roll Forward]
Beginning Balance	219	728	173
Cost Incurred	7,846	15,362	14,254
Payments	(8,065)	(15,871)	(13,699)
Non-cash adjustments	0	0	0
Ending Balance	0	219	728
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Cost Incurred	1,469	1,326	2,390
Payments	0	0	0
Non-cash adjustments	(1,469)	(1,326)	(2,390)
Ending Balance	0	0	0
Asset write-down
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Cost Incurred	3,033	296	915
Payments	0	0	0
Non-cash adjustments	(3,033)	(296)	(915)
Ending Balance	0	0	0
Japan
Restructuring Reserve [Roll Forward]
Cost Incurred	9	258	372
Transformation costs	416	158	131
EMEA
Restructuring Reserve [Roll Forward]
Cost Incurred	3,210	3,310	1,444
Transformation costs	961	838	1,260
North America Plasma
Restructuring Reserve [Roll Forward]
Cost Incurred	0	360	42
Transformation costs	0	28	0
All Other
Restructuring Reserve [Roll Forward]
Cost Incurred	19,836	32,935	47,193
Transformation costs	$ 17,852	$ 31,810	$ 34,264

CAPITALIZATION OF SOFTWARE DE81

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Capitalization of Software and Development Costs [Abstract]
Capitalized software development costs for ongoing initiatives		$ 17	$ 9.5
Software costs capitalized, net	$ 54.9	54.9	39.7
Total costs capitalized related to in process software development initiatives	14.4	14.4	7.9
Interest costs capitalized		0.2	0.2
Capitalized costs amortized (placed into service)		8.7	15.7
Amortization of capitalized software development cost expense		$ 10.9	$ 3.2	$ 1.1
Impairment charges related to the discontinuance of certain capitalized software projects	$ 6

SUMMARY OF QUARTERLY DATA (UN82

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Summary of Quarterly Data [Line Items]
Net revenues	$ 242,342	$ 233,384	$ 219,693	$ 213,413	$ 226,478	$ 231,827	$ 227,580	$ 224,488	$ 908,832	$ 910,373	$ 938,509
Gross profit	89,223	108,855	105,297	102,539	108,365	111,661	108,114	106,278	405,914	434,418	468,365
Operating income (loss)	(5,550)	(61,177)	19,179	3,606	11,539	18,260	12,407	(1,666)	(43,942)	40,540	46,432
Net (loss) income	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ (55,579)	$ 16,897	$ 35,148
Per share data:
Basic (loss) income per share (in dollars per share)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.06)	$ 0.31	$ 0.15	$ (0.07)	$ (1.09)	$ 0.33	$ 0.68
Diluted (loss) income per share (in dollars per share)	$ (0.17)	$ (1.17)	$ 0.25	$ (0.01)	$ (0.06)	$ 0.31	$ 0.14	$ (0.07)	$ (1.09)	$ 0.32	$ 0.67
Understatement of Provision for Income Taxes, Immaterial [Member]
Summary of Quarterly Data [Line Items]
Operating income (loss)				$ (800)
Net (loss) income				$ 200
Overstated Liability, Immaterial [Member]
Summary of Quarterly Data [Line Items]
Operating income (loss)		$ 4,100
Net (loss) income		$ 4,000
Correction of Certain Out of Period Items, Immaterial [Member]
Summary of Quarterly Data [Line Items]
Operating income (loss)	$ (2,900)
Net (loss) income	$ (1,800)

ACCUMULATED OTHER COMPREHENSI83

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	$ (21,724)	$ 1,410
Other comprehensive income before reclassifications	(5,041)	(16,749)
Amounts reclassified from Accumulated Other Comprehensive Income	(8,275)	(6,385)
Other comprehensive loss	(13,316)	(23,134)	$ (4,023)
Accumulated Other Comprehensive Income, Balance	(35,040)	(21,724)	1,410
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(20,512)	3,198
Other comprehensive income before reclassifications	(1,987)	(23,710)
Amounts reclassified from Accumulated Other Comprehensive Income	0	0
Other comprehensive loss	(1,987)	(23,710)
Accumulated Other Comprehensive Income, Balance	(22,499)	(20,512)	3,198
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(8,923)	(4,592)
Other comprehensive income before reclassifications	884	(4,410)
Amounts reclassified from Accumulated Other Comprehensive Income	547	79
Other comprehensive loss	1,431	(4,331)
Accumulated Other Comprehensive Income, Balance	(7,492)	(8,923)	(4,592)
Net Unrealized Gain/loss on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	7,711	2,804
Other comprehensive income before reclassifications	(3,938)	11,371
Amounts reclassified from Accumulated Other Comprehensive Income	(8,822)	(6,464)
Other comprehensive loss	(12,760)	4,907
Accumulated Other Comprehensive Income, Balance	$ (5,049)	$ 7,711	$ 2,804

ACCUMULATED OTHER COMPREHENSI84

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 2) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Apr. 02, 2016	Dec. 26, 2015	Sep. 26, 2015	Jun. 27, 2015	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									$ (9,474)	$ (9,375)	$ (10,031)
Income tax effect									(2,163)	(14,268)	(1,253)
Net (loss) income	$ (8,735)	$ (59,440)	$ 12,863	$ (267)	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	(55,579)	16,897	$ 35,148
Net Unrealized Gain/loss on Derivatives | Amounts Reclassified from Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									8,654	6,736
Income tax effect									168	(272)
Net (loss) income									8,822	6,464
Defined benefit plans | Amounts Reclassified from Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									602	123
Income tax effect									(55)	(44)
Net (loss) income									$ 547	$ 79

VALUATION AND QUALIFYING ACCO85

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2016	Mar. 28, 2015	Mar. 29, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Fiscal Year	$ 1,749	$ 1,676	$ 1,727
Charged to Costs and Expenses	728	399	186
Write-Offs (Net of Recoveries)	(224)	(326)	(237)
Balance at End of Fiscal Year	$ 2,253	$ 1,749	$ 1,676